Document:

AMENDMENT
NO. 4 TO

LOAN
AND SECURITY AGREEMENT

 

This
AMENDMENT NO. 4 TO LOAN AND SECURITY AGREEMENT AND CONSENT (this “Amendment No. 4”) is entered into
as of November 8, 2019, by and among Wireless Telecom Group, Inc., a New
Jersey corporation (“WTG”), BOONTON ELECTRONIC CORPORATION, a New Jersey corporation (“Boonton”),
MICROLAB/FXR LLC, a New Jersey limited liability company (“Microlab” and, together with WTG and Boonton,
collectively, “Borrowers”), and BANK OF AMERICA, N.A. (“Lender”). Capitalized
terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Loan Agreement.

 

RECITALS

 

WHEREAS,
Borrowers and Lender have entered into a Loan and Security Agreement, dated as of February 16, 2017 (as amended, restated, supplemented
and otherwise modified from time to time in accordance with its provisions, the “Loan Agreement”);

 

WHEREAS,
Borrowers have requested that Lender agree, and Lender has agreed, to amend the Loan Agreement on the terms and subject to the
conditions set forth herein; and

 

WHEREAS,
pursuant to Section 12.1.2 of the Loan Agreement, the amendments and consents requested by Borrowers must be contained in a written
agreement signed by Borrowers and Lender;

 

NOW,
THEREFORE, in consideration of the premises set forth above and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties agree as follows:

 

SECTION
1. CONFIRMATION BY BORROWERS OF OBLIGATIONS.

 

Borrowers
hereby acknowledge, confirm and agree that, as of November 8, 2019, Borrowers are indebted to Lender for Revolver Loans in the
aggregate outstanding principal amount of $2,464,146.57, the Term Loan in the aggregate outstanding principal amount of $342,000.00
and Letters of Credit in the aggregate outstanding face amount of $0, together with interest accrued and accruing thereon. The
foregoing amounts do not include other fees, expenses and other amounts that are chargeable or otherwise reimbursable under the
Loan Agreement. Borrowers do not have any rights of offset, defenses, claims or counterclaims with respect to any of the Obligations.

 

SECTION
2. ACKNOWLEDGMENTS.

 

2.1
Acknowledgment of Security Interests. Borrowers hereby acknowledge, confirm and agree that Lender,
for the benefit of Secured Parties, has and shall continue to have valid, enforceable and perfected first priority Liens, subject
to Permitted Liens, upon and security interests in the Collateral of Borrowers heretofore granted to Lender, for the benefit of
Secured Parties, pursuant to the Loan Documents or otherwise granted to or held by Lender, for the benefit of Secured Parties,
and upon and in which Lender, for the benefit of Secured Parties, presently has perfected first priority Liens and security interests.

 

2.2
Binding Effect of Documents. Each Borrower hereby acknowledges, confirms and agrees that: (a)
each of the Loan Documents to which it is a party has been duly executed and delivered, and each is in full force and effect as
of the date hereof, (b) the agreements and obligations of each Borrower contained in the Loan Documents and in this Amendment
constitute the legal, valid and binding obligations of each Borrower, enforceable against it in accordance with their respective
terms, and each Borrower has no valid defense to the enforcement of such obligations, except as limited by applicable bankruptcy,
insolvency, reorganization, moratorium, or similar laws affecting the rights of creditors generally and to the effect of general
principles of equity whether applied by a court of law or equity, and (c) Lender is and shall be entitled to the rights, remedies
and benefits provided for in the Loan Documents and applicable law.

 

    	 	 	 

    	 

    

 

SECTION
3. AMENDMENTS. Effective as of the date hereof:

 

3.1
The definition of “Term Loan Maturity Date” now appearing in Section 1.1 of the
Loan Agreement is hereby amended and restated in its entirety to read as follows:

 

“Term
Loan Maturity Date: March 31, 2020.”

 

SECTION
4. REPRESENTATIONS, WARRANTIES AND COVENANTS.

 

Each
Borrower hereby represents, warrants and covenants with and to Lender as follows:

 

4.1
Representations in Loan Documents. Each of the representations and warranties made by or on
behalf of such Borrower to Lender in any of the Loan Documents was true and correct in all material respects when made (except
for those representations and warranties that are already qualified by concepts of materiality or by express thresholds, which
representations and warranties shall be true and correct in all respects) and is true and correct in all material respects on
and as of the date of this Amendment with the same full force and effect as if each of such representations and warranties had
been made by or on behalf of such Borrower on the date hereof and in this Amendment (other than such representations and warranties
that relate solely to a specific prior date). 

 

4.2
Binding Effect of Documents. This Amendment and the other Loan Documents have been duly executed
and delivered to Lender by such Borrower and are in full force and effect, as modified hereby.

 

4.3
No Conflict, Etc. The execution, delivery and performance of this Amendment by such Borrower
will not violate or cause a default under any applicable law or material contract of such Borrower and will not result in, or
require, the creation or imposition of any Lien on any of its properties or revenues, other than Permitted Liens.

 

4.4
No Default or Event of Default. No Default or Event of Default exists immediately prior to the
execution of this Amendment and no Default or Event of Default will exist immediately after the execution of this Amendment and
the other documents, instruments and agreements executed and delivered in connection herewith.

 

4.5
Additional Events of Default. Any misrepresentation by such Borrower, or any failure of such
Borrower to comply with the covenants, conditions and agreements contained in any Loan Document, herein or in any other document,
instrument or agreement at any time executed and/or delivered by such Borrower with, to or in favor of Lender shall, subject to
the terms and provisions of the Loan Agreement and the other Loan Documents, constitute an Event of Default hereunder, under the
Loan Agreement and the other Loan Documents.

 

4.6
Certificate of Beneficial Ownership.

 

(a)
As of the Effective Date (as hereinafter defined), the information included in the Beneficial Ownership Certification is true
and correct in all respects.

 

(b)
Promptly following any request therefor, Borrowers shall provide information and documentation reasonably requested by Lender
for purposes of compliance with applicable “know your customer” requirements under the PATRIOT Act, the Beneficial
Ownership Regulation or other applicable anti-money laundering laws.

 

    	 	2	 

    	 

    

 

SECTION
5. CONDITIONS TO EFFECTIVENESS OF THIS AMENDMENT.

 

This
Amendment shall become effective upon the date (the “Effective Date”) on which Lender shall have received:

 

(a)
this Amendment, in form and substance satisfactory to Lender in its sole discretion, duly authorized, executed and delivered by
each Borrower and Lender; and

 

(b)
(i) an amendment fee in the amount of $10,000, which fee shall be earned in full as of the Effective Date and shall be non-refundable,
and (ii) all other fees required to be paid, and all expenses for which invoices have been presented, in each case in connection
with this Amendment (including reasonable fees, disbursements and other charges of counsel to Lender).

 

SECTION
6. PROVISIONS OF GENERAL APPLICATION.

 

6.1
Effect of this Amendment. Except as modified pursuant hereto, and pursuant to the other documents,
instruments and agreements executed and delivered in connection herewith, no other changes or modifications to the Loan Documents
are intended or implied and in all other respects the Loan Documents are hereby specifically ratified, restated and confirmed
by all parties hereto as of the effective date hereof. To the extent of conflict between the terms of this Amendment and the other
Loan Documents, the terms of this Amendment shall control. Any Loan Document amended hereby shall be read and construed with this
Amendment as one agreement.

 

6.2
Costs and Expenses. Borrowers absolutely and unconditionally agree to pay to Lender, on demand
by Lender at any time and as often as the occasion therefor may require, whether or not all or any of the transactions contemplated
by this Amendment are consummated: all reasonable fees and disbursements of any counsel to Lender in connection with the preparation,
negotiation, execution, or delivery of this Amendment and any agreements delivered in connection with the transactions contemplated
hereby and all reasonable out-of-pocket expenses which shall at any time be incurred or sustained by Lender or its directors,
officers, employees or agents as a consequence of or in any way in connection with the preparation, negotiation, execution, or
delivery of this Amendment and any agreements prepared, negotiated, executed or delivered in connection with the transactions
contemplated hereby.

 

6.3
No Third Party Beneficiaries. The terms and provisions of this Amendment shall be for the benefit
of the parties hereto and their respective successors and assigns; no other person, firm, entity or corporation shall have any
right, benefit or interest under this Amendment.

 

6.4
Further Assurances. The parties hereto shall execute and deliver such additional documents and
take such additional action as may be reasonably necessary or desirable to effectuate the provisions and purposes of this Amendment.

 

6.5
Binding Effect. This Amendment shall be binding upon and inure to the benefit of each of the
parties hereto and their respective successors and assigns.

 

6.6
Merger. This Amendment sets forth the entire agreement and understanding of the parties with
respect to the matters set forth herein. This Amendment cannot be changed, modified, amended or terminated except in a writing
executed by the party to be charged.

 

6.7
Survival of Representations and Warranties. All representations and warranties made in this
Amendment or any other document furnished in connection with this Amendment shall survive the execution and delivery of this Amendment
and the other documents, and no investigation by Lender or any closing shall affect the representations and warranties or the
right of Lender to rely upon them.

 

    	 	3	 

    	 

    

 

6.8
Severability. Any provision of this Amendment held by a court of competent jurisdiction to be
invalid or unenforceable shall not impair or invalidate the remainder of this Amendment.

 

6.9
Reviewed by Attorneys. Each Borrower represents and warrants to Lender that it (a) understands
fully the terms of this Amendment and the consequences of the execution and delivery of this Amendment, (b) has been afforded
an opportunity to have this Amendment reviewed by, and to discuss this Amendment and each document executed in connection herewith
with, such attorneys and other persons as such Borrower may wish, and (c) has entered into this Amendment and executed and delivered
all documents in connection herewith of its own free will and accord and without threat, duress or other coercion of any kind
by any Person. The parties hereto acknowledge and agree that neither this Amendment nor the other documents executed pursuant
hereto shall be construed more favorably in favor of one than the other based upon which party drafted the same, it being acknowledged
that all parties hereto contributed substantially to the negotiation and preparation of this Amendment and the other documents
executed pursuant hereto or in connection herewith.

 

6.10
Governing Law; Consent to Jurisdiction and Venue.

 

(a)
THIS AMENDMENT, UNLESS OTHERWISE SPECIFIED, SHALL BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK, WITHOUT GIVING EFFECT TO ANY
CONFLICT OF LAW PRINCIPLES (BUT GIVING EFFECT TO FEDERAL LAWS RELATING TO NATIONAL BANKS).

 

(b)
EACH BORROWER HEREBY CONSENTS TO THE NON-EXCLUSIVE JURISDICTION OF ANY FEDERAL OR STATE COURT SITTING IN OR WITH JURISDICTION
OVER THE STATE OF NEW YORK, IN ANY PROCEEDING OR DISPUTE RELATING IN ANY WAY HERETO, AND AGREES THAT ANY SUCH PROCEEDING SHALL
BE BROUGHT BY IT SOLELY IN ANY SUCH COURT. EACH BORROWER IRREVOCABLY WAIVES ALL CLAIMS, OBJECTIONS AND DEFENSES THAT IT MAY HAVE
REGARDING SUCH COURT’S PERSONAL OR SUBJECT MATTER JURISDICTION, VENUE OR INCONVENIENT FORUM. EACH PARTY HERETO IRREVOCABLY
CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN SECTION 12.3.1 OF THE LOAN AGREEMENT. Nothing herein shall
limit the right of Lender to bring proceedings against any Obligor in any other court, nor limit the right of any party to serve
process in any other manner permitted by Applicable Law. Nothing in this Amendment shall be deemed to preclude enforcement by
Lender of any judgment or order obtained in any forum or jurisdiction.

 

6.11
Waivers. TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, EACH BORROWER WAIVES (A) THE RIGHT
TO TRIAL BY JURY (WHICH LENDER HEREBY ALSO WAIVES) IN ANY PROCEEDING OR DISPUTE OF ANY KIND RELATING IN ANY WAY HERETO; (B) PRESENTMENT,
DEMAND, PROTEST, NOTICE OF PRESENTMENT, DEFAULT, NON-PAYMENT, MATURITY, RELEASE, COMPROMISE, SETTLEMENT, EXTENSION OR RENEWAL
OF ANY COMMERCIAL PAPER, ACCOUNTS, DOCUMENTS, INSTRUMENTS, CHATTEL PAPER AND GUARANTIES AT ANY TIME HELD BY LENDER ON WHICH A
BORROWER MAY IN ANY WAY BE LIABLE, AND HEREBY RATIFIES ANYTHING LENDER MAY DO IN THIS REGARD; (C) NOTICE PRIOR TO TAKING POSSESSION
OR CONTROL OF ANY COLLATERAL; (D) ANY BOND OR SECURITY THAT MIGHT BE REQUIRED BY A COURT PRIOR TO ALLOWING LENDER TO EXERCISE
ANY RIGHTS OR REMEDIES; (E) THE BENEFIT OF ALL VALUATION, APPRAISEMENT AND EXEMPTION LAWS; (F) ANY CLAIM AGAINST LENDER, ON ANY
THEORY OF LIABILITY, FOR SPECIAL, INDIRECT, CONSEQUENTIAL, EXEMPLARY OR PUNITIVE DAMAGES (AS OPPOSED TO DIRECT OR ACTUAL DAMAGES)
IN ANY WAY RELATING TO ANY ENFORCEMENT ACTION, OBLIGATIONS, LOAN DOCUMENTS OR TRANSACTIONS RELATING THERETO; AND (G) NOTICE OF
ACCEPTANCE HEREOF. Each Borrower acknowledges that the foregoing waivers are a material inducement to Lender entering into this
Amendment and that Lender are relying upon the foregoing in their dealings with Borrowers. Each Borrower has reviewed the foregoing
waivers with its legal counsel and knowingly and voluntarily has waived its jury trial and other rights following consultation
with legal counsel. In the event of litigation, this Amendment may be filed as a written consent to a trial by the court.

 

6.12
Counterparts. This Amendment may be executed in one or more counterparts, each of which shall
constitute but one and the same agreement. In making proof of this Amendment, it shall not be necessary to produce or account
for more than one counterpart hereof signed by each of the parties hereto. Delivery of an executed counterpart of this Amendment
electronically or by facsimile shall be effective as delivery of an original executed counterpart of this Amendment.

 

[Signature
page follows]

 

    	 	4	 

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have duly executed this Amendment as of the date first written above.

 

	 	WIRELESS TELECOM GROUP, INC.
	 	 	 
	 	By:	/s/
    Michael Kandell     
	 	Name:	Michael
    Kandell
	 	Title:	Chief
    Financial Officer
	 	 	 
	 	BOONTON ELECTRONIC CORPORATION 
	 	 	 
	 	By:	/s/
    Michael Kandell
	 	Name:	Michael
    Kandell
	 	Title:	Chief
    Financial Officer
	 	 	 
	 	MICROLAB/FXR LLC
	 	 	 
	 	By:	/s/
    Michael Kandell
	 	Name:	Michael
    Kandell
	 	Title:	Chief
    Financial Officer
	 	 	 
	 	BANK OF AMERICA, N.A.
	 	 	 
	 	By:	/s/
    Galina Evelson
	 	Name:	Galina
    Evelson
	 	Title:	Vice
    PresidentExhibit 10.1

 

Execution
Copy

 

CERTAIN INFORMATION IDENTIFIED WITH
THE MARK “(***)”, “(***%***)” AND “(***$***)” HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE SUCH
INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

 

OPTION AND
LICENSE AGREEMENT

 

by and BETWEEN

 

MEDIMMUNE
LIMITED

 

and

 

AEVI GENOMIC
MEDICINE, INC.

 

    

     

    

 

TABLE OF
CONTENTS

 

	ARTICLE 1	 
		OPTION	1
	 	1.1.	Binding Provisions on the Agreement Effective Date	1
	 	1.2.	Aevi’s Option to Make Entire Agreement Binding	1
	 	1.3.	Covenants of MedImmune	2
	 	1.4.	Competition Law Approvals	2
	ARTICLE 2	 
		DEFINITIONS	2
	 	2.1.	Definitions	2
	 	2.2.	Additional Definitions	11
	ARTICLE 3	 
		LICENSES AND INTELLECTUAL PROPERTY OWNERSHIP	12
	 	3.1.	License Grant	12
	 	3.2.	Sublicenses	12
	 	3.3.	Ownership of and Rights to Intellectual Property	12
	 	3.4.	MedImmune Covenant to Aevi	13
	 	3.5.	No Other Rights	13
	ARTICLE 4 	 
	 	TECHNOLOGY TRANSFER	13
	 	4.1.	Technology Transfer	13
	 	4.2.	Antibody Material and Clinical Material	13
	 	4.3.	Cell Line	14
	 	4.4.	Disclaimers	14
	ARTICLE 5 	 
	 	DEVELOPMENT, MANUFACTURE AND RELATED DILIGENCE	14
	 	5.1.	Development	14
	 	5.2.	Specific Development Responsibilities	15
	 	5.3.	Third Parties	15
	ARTICLE 6 	 
	 	COMMERCIALIZATION AND RELATED DILIGENCE	16
	 	6.1.	Diligence in Commercialization	16
	 	6.2.	Commercialization	16
	 	6.3.	Commercial Manufacturing and Supply	16
	 	6.4.	Medical and Scientific Affairs	16

 

     -i-

     

    

 

	ARTICLE 7	 
		FINANCIAL PROVISIONS	16
	 	7.1.	Licensee Fees	16
	 	7.2.	Milestones	18
	 	7.3.	Royalties	19
	 	7.4.	Reports and Royalty Payments	19
	 	7.5.	Payment Provisions Generally	19
	 	7.6. 	Maintenance of Records; Audits	21
	ARTICLE 8 	 
	 	INTELLECTUAL PROPERTY PROTECTION AND RELATED MATTERS	22
	 	8.1.	Filing, Prosecution and Maintenance of MedImmune Patent Rights	22
	 	8.2.	Invalidity or Unenforceability Defenses or Actions	23
	 	8.3.	Enforcement of Patent Rights	23
	 	8.4.	Biosimilar Arrangements	25
	 	8.5.	Claimed Infringement of Third Party Rights	26
	 	8.6.	Product Trademarks	27
	 	8.7.	Patent Term Extensions in the Territory	28
	ARTICLE 9	 
		CONFIDENTIALITY	28
	 	9.1.	Confidential Information	28
	 	9.2.	Required Disclosures	28
	 	9.3.	Permitted Disclosures	29
	 	9.4.	Public Announcements and Use of Names	29
	ARTICLE 10	 
		TERM AND TERMINATION	29
	 	10.1.	Term	29
	 	10.2.	Termination by MedImmune.	30
	 	10.3.	Termination by Aevi	30
	 	10.4.	Effects of Termination	31
	 	10.5. 	Rights in Bankruptcy	33
	 	10.6.	Return of Confidential Information	34
	 	10.7. 	Survival	34
	ARTICLE 11 	 
	 	REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION	34
	 	11.1.	Mutual Representations and Warranties	34
	 	11.2. 	MedImmune Representations and Warranties	35
	 	11.3.	Aevi Representations and Warranties	38
	 	11.4.	Warranty Disclaimer	39
	 	11.5.	No Consequential Damages	39
	 	11.6. 	Indemnification and Insurance	40

 

     -ii-

     

    

 

	ARTICLE 12 	 
	 	MISCELLANEOUS PROVISIONS	41
	 	12.1.	Governing Law	41
	 	12.2.	Jurisdiction; Venue; Service of Process	41
	 	12.3.	Assignment	42
	 	12.4.	Amendments	42
	 	12.5.	Notices	43
	 	12.6.	Force Majeure	43
	 	12.7. 	Compliance with Export Regulations	44
	 	12.8.	Independent Contractors	44
	 	12.9.	Further Assurances	44
	 	12.10.	No Strict Construction	44
	 	12.11.	Performance by Affiliates	44
	 	12.12.	Construction	44
	 	12.13. 	Headings	45
	 	12.14.	No Implied Waivers; Rights Cumulative	45
	 	12.15.	Severability	45
	 	12.16.	No Third Party Beneficiaries	45
	 	12.17.	Dispute Resolution	45
	 	12.18.	Execution in Counterparts	45

 

Schedules 

 

Schedule 2.1.46 – MedImmune Know-How

Schedule 2.1.47 – MedImmune Patent Rights

Schedule 4.2 – Antibody Material to be Provided to Aevi

Schedule 4.3 – Cell Line to be Provided to Aevi

  

Exhibits

 

Exhibit A – Press Release

 

     -iii-

     

    

 

 

OPTION AND
LICENSE AGREEMENT

 

This Option and License Agreement (this
 “Agreement”) dated the 6th day of August 2019 (the “Agreement Effective Date”)
is by and between MedImmune Limited, a company organized under the laws of England and Wales “MedImmune”),
and Aevi Genomic Medicine, Inc., a Delaware corporation (“Aevi”). MedImmune and Aevi may each be referred
to herein individually as a “Party” and collectively as the “Parties.”

 

INTRODUCTION

 

WHEREAS, MedImmune owns or otherwise controls
certain intellectual property relating to MEDI2338, a fully human anti-IL-18 monoclonal antibody;

 

WHEREAS, Aevi is a pharmaceutical company
with a focus on developing and commercializing products for the treatment of various diseases; and

 

WHEREAS, Aevi is interested in developing
and commercializing products that contain MEDI2338 on the terms and conditions set forth herein.

 

NOW, THEREFORE, in consideration of the
mutual promises and covenants set forth below and other good and valuable consideration, the receipt and sufficiency of which is
hereby acknowledged, the Parties hereby agree as follows:

 

Article
1 

OPTION

 

1.1.         Binding Provisions on the Agreement Effective Date. Upon the Agreement Effective Date, only Article 1, Article 2,
and Article 9 through Article 12 shall be binding on, and in full force and effect between, the Parties.

 

1.2.         Aevi’s Option to Make Entire Agreement Binding. At Aevi’s option, all Articles of this Agreement shall
immediately become binding on, and in full force and effect between, the Parties upon Aevi giving MedImmune written notice of its
exercise of such option (the “Election Notice”) no later than 5:00 PM Eastern Time on the date that is
(***) after the Agreement Effective Date (the “Deadline”); provided that Aevi may not exercise such option
before the first date on which (a) Aevi has closed a transaction or series of transactions pursuant to which Aevi issues and sells
shares of Common Stock and/or securities exercisable or convertible into Common Stock from which Aevi receives at least (***) (***$***)
of gross proceeds and (b) the Competition Law Approvals have been received. The Parties may agree to extend the Deadline by a maximum
of (***) successive (***) periods (with each (***) period agreed being the “Extended Deadline”); provided,
however, that (i) if all Competition Law Approvals sought by the Parties have not been obtained by the Deadline (or the first Extended
Deadline, as the case may be), each Extended Deadline shall be automatically effective and (ii) except as set forth in the preceding
clause (i), in no event shall either Party be obligated to agree to any Extended Deadline. The date of Aevi’s Election Notice
is referred to in this Agreement as the “License Effective Date.”

 

     

     

    

 

1.3.         Covenants
of MedImmune. During the Term, MedImmune shall not enter into any negotiations, option, license or other agreement with any
Third Party regarding the evaluation, development, license, sale, transfer, disposition or commercialization of any of the MedImmune
Intellectual Property or the Molecule in the Field.

 

1.4.         Competition Law Approvals.

 

1.4.1.     
Filing. No later than five (5) Business Days after the Agreement Effective Date, the Parties shall agree as to whether
Competition Law Approvals should be sought in any jurisdiction. With respect to each jurisdiction from which the Parties agree
to seek Competition Law Approvals, each Party shall file or cause to be filed all necessary requests for Competition Law Approvals
to the relevant Governmental Entity. Each Party shall respond as promptly as practicable to any inquiries or requests received
from any Governmental Entity for additional information or documentation and, subject to the proviso in Section 1.4.2, use Commercially
Reasonable Efforts to cause the waiting periods under the applicable Competition Laws to terminate or expire at the earliest possible
date after the date of filing. Each Party shall be responsible for its own legal fees in connection with the preparation of its
portion of the notifications required under the applicable Competition Laws, and each Party shall be responsible for fifty percent
(50%) of any filing fees of both Parties with respect thereto.

 

1.4.2.     
Cooperation. The Parties shall cooperate with each other to obtain the mutually agreed Competition Law Approvals
as promptly as practicable following the Agreement Effective Date; provided, however, in no event shall either Party or any of
its Affiliates be required (in order to obtain any such Competition Law Approval) to (a) divest or hold separate any of its or
their respective businesses, product lines or assets or (b) take or agree to take any other action or agree to any limitation with
respect to any of its or their respective businesses, product lines or assets.

 

Article
2 

DEFINITIONS

 

2.1.         Definitions. When used in this Agreement, each of the following terms shall have the following meanings:

 

2.1.1.     
“Accounting Standards” means with respect to a Party, as applicable, (a) United States generally
accepted accounting principles (“GAAP”) or (b) International Financial Reporting Standards, in each case
consistently applied.

 

2.1.2.     
“Aevi Improvements” means any and all Improvements to the MedImmune Intellectual Property, Aevi
Patent Rights or Aevi Know-How created, conceived or reduced to practice by Aevi, or its Affiliates, agents, or sublicensees or
by Third Parties acting on Aevi’s or its Affiliates’, agents’, or sublicensees’ behalf, while performing
activities under this Agreement.

 

2.1.3.     
“Aevi Intellectual Property” means Aevi Know-How, Aevi Patent Rights and Aevi Improvements.

 

    	 	-2-	 

     

    

 

2.1.4.     
“Aevi Know-How” means Know-How that (a) is owned by Aevi or any of its Affiliates during the Term,
and (b) is entirely related to the Molecule or a Product, and (c) is reasonably necessary or useful in connection with the Development,
Manufacture, use or Commercialization of the Molecule or a Product in the Field.

 

2.1.5.     
“Aevi Patent Rights” means any Patent Rights claiming any composition or method of making or method
of use of the Molecule or a Product that (a) are owned by Aevi or any of its Affiliates during the Term, and (b) are entirely related
to the Molecule or a Product, and (c) are reasonably necessary or useful in connection with the Development, Manufacture, use or
Commercialization of the Molecule or a Product in the Field.

 

2.1.6.     
“Affiliate” means, with respect to any Person, any other Person which controls, is controlled
by, or is under common control with such Person as of or after the Agreement Effective Date. A Person shall be regarded as in control
of another entity if it owns or controls fifty percent (50%) or more of the equity securities of the subject entity entitled to
vote in the election of directors (or, in the case of an entity that is not a corporation, for the election of the corresponding
managing authority) or has the power to control the management and policies of the subject entity, whether through ownership, contract
or otherwise.

 

2.1.7.     
“Annual Net Sales” means the combined Net Sales for all Products in the Territory within a Contract
Year.

 

2.1.8.     
 “Applicable Law” means, with respect to a country in the Territory, the laws, rules and regulations,
including any rules, regulations, guidelines or other requirements of the Regulatory Authorities applicable to the Development,
Manufacturing or Commercialization of Products, that may be in effect from time to time in such country.

 

2.1.9.     
“Bankruptcy Code” means Title 11, United States Code, as amended, or analogous provisions of Applicable
Law outside the United States.

 

2.1.10.   
“Biosimilar” means, with respect to a reference brand biologic product and a particular jurisdiction,
a biologic product: (a) that is highly similar to such reference brand biologic product notwithstanding minor differences in clinically
inactive components; (b) has no clinically meaningful differences from such reference brand biologic product in terms of safety,
purity and potency; and (c) for which a Biosimilar Application is approved by the relevant Regulatory Authority of such jurisdiction.

 

2.1.11. 
   “Biosimilar Application” means a Regulatory Approval Application for a product claimed to be biosimilar
or interchangeable to any Product, or otherwise relying on the approval of such Product, in each case in accordance with Applicable
Law in the jurisdiction in which the product is sought to be marketed and sold.

 

2.1.12. 
   “BLA” means a Biologics License Application filed with FDA or the equivalent thereof filed with
any other Regulatory Authority.

 

2.1.13.   
“Blocking Patent” means any Patent Rights owned or controlled by a Third Party that are infringed
or are reasonably likely to be infringed by the manufacture, use, offer for sale, sale or import of the Molecule or the Molecule
that is a part of a Product in the Field in the Territory.

 

    	 	-3-	 

     

    

 

2.1.14. 
   “Business Day” means a day on which banking institutions in New York, New York are open for business.

 

2.1.15.   
“Change of Control” means, with respect to a Party, (a) a merger or consolidation of such Party
with a Third Party which results in the stockholders or equity holders of such Party not owning at least fifty percent (50%) of
the combined voting power of the surviving entity immediately after such merger or consolidation, or (b) except in the case of
a bona fide equity or debt financings, whether private or public, in which a Party issues new shares of its capital stock or securities
convertible into shares of such Party, a transaction or series of related transactions in which a Third Party, together with its
Affiliates, becomes the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities
of such Party, or (c) the sale or other transfer to a Third Party of all or substantially all of such Party’s business to
which the subject matter of this Agreement relates.

 

2.1.16. 
   “CMC” means chemistry, manufacturing and controls.

 

2.1.17. 
  “Combination Product” means a Product that is comprised of or contains the Molecule as an active
ingredient together with one (1) or more other active ingredients and is sold either as a fixed dose/unit or as separate doses/units.

 

2.1.18. 
   “Commercialization” means any and all activities constituting using, marketing, promoting, distributing,
offering for sale, selling and importing a Product in the Field in the Territory and shall include, but not be limited to, promotion,
as well as activities required to fulfill ongoing post-approval regulatory obligations, including adverse event reporting and sales
force training. When used as a verb, “Commercialize” means to engage in Commercialization.

 

2.1.19.   
“Commercially Reasonable Efforts” means a measure of effort consistent with Applicable Law and
industry standards and practices followed by pharmaceutical companies in the United States of similar size and resources as Aevi
and its Affiliates in total with respect to their pharmaceutical products of a similar value, stage, development, life cycle, and
commercial potential, taking into consideration safety and efficacy, development costs, the anticipated prescription label and
all other relevant factors, including, without limitation, the nature of the Product and the clinical setting in which it is expected
to be used.

 

2.1.20. 
   “Common Stock” means Aevi’s common stock, par value $0.0001 per share.

 

2.1.21.   
“Competition Law Approvals” means all consents and approvals of, and declarations and filings
with, Governmental Entities, and all applicable waiting periods (and any extensions thereof), required pursuant to applicable Competition
Laws in order for MedImmune to lawfully grant to Aevi the licenses under the MedImmune Intellectual Property contemplated by this
Agreement.

 

2.1.22. 
   “Competition Laws” means HSR and all rules and regulations issued thereunder and any similar laws,
rules and regulations of any foreign jurisdiction that may require the consent and/or approval of, or declaration or filings with,
a Governmental Entity in order for MedImmune to lawfully grant to Aevi the licenses under the MedImmune Intellectual Property contemplated
by this Agreement.

 

    	 	-4-	 

     

    

 

2.1.23.   
“Confidential Information” means, with respect to each Party, proprietary data or information
that belong in whole or in part to such Party, its Affiliates or sublicensees, including, without limitation, (a) all MedImmune
Intellectual Property, MedImmune Excluded IP, and Aevi Intellectual Property, (b) any information designated as Confidential Information
of such Party hereunder, in all cases that, if disclosed in writing, is marked with the words “Confidential,” “Proprietary”
or words of similar import, and if disclosed orally or visually, is described in reasonable detail in a written notice sent by
the Disclosing Party to the Receiving Party within thirty (30) days of the oral or visual disclosure requesting that such information
be treated as Confidential Information hereunder and (c) all information that a reasonable person would understand to be confidential
or proprietary in nature, whether or not marked as such.

 

2.1.24.   
“Confidentiality Agreement” means the Mutual Confidentiality Agreement dated March 3, 2017 between
MedImmune and Aevi.

 

2.1.25. 
   “Contract Quarters” means the successive three (3) month periods in each Contract Year ending
on March 31, June 30, September 30 or December 31.

 

2.1.26.   
“Contract Year” means the twelve (12) month period beginning on January 1 and ending on December
31 of each calendar year, provided, however, that the first Contract Year shall be the period of time beginning on the License
Effective Date and ending on December 31 of that year. Each Contract Year, except the first Contract Year, shall be divided into
four (4) Contract Quarters.

 

2.1.27. 
   “Control” or “Controlled” means with respect to any (a) material, item
of information, method, data or other Know-How, or (b) intellectual property right, the possession (whether by ownership or license,
other than pursuant to this Agreement) by a Party or its Affiliates of the ability to grant to the other Party access and/or a
license as provided herein under such item or right without violating any Third Party rights thereto or the terms of any agreement
or other arrangement with any Third Party existing before or after the License Effective Date.

 

2.1.28. 
   “Development” means all pre-clinical, clinical, CMC and regulatory activities with respect to
a Product in the Field in a given country in the Territory from the License Effective Date until Regulatory Approval of such Product
in such country is obtained for the indication under study. When used as a verb, “Develop” means to engage
in Development.

 

2.1.29.   
“EU5” means France, Germany, Italy, Spain and the United Kingdom.

 

2.1.30.   
 “Executive Officers” means the Chief Executive Officer and President of Aevi (or an executive
of Aevi designated by such person(s)) and the Executive Director and Chief Executive Officer of AstraZeneca plc (or an executive
of AstraZeneca plc or MedImmune designated by such Chief Executive Officer).

 

    	 	-5-	 

     

    

 

2.1.31.   
“FD&C Act” means the U.S. Federal Food, Drug, and Cosmetic Act, as amended from time to time
(21 U.S.C. Section 301 et seq.), together with any rules and regulations promulgated thereunder.

 

2.1.32.   
“FDA” means the United States Food and Drug Administration, or a successor agency in the United
States with responsibilities comparable to those of the United States Food and Drug Administration.

 

2.1.33.   
“Field” means all indications and uses in human health.

 

2.1.34. 
   “First Commercial Sale” means, with respect to a given Product in a country in the Territory,
the first commercial sale in an arms-length transaction of such Product to a Third Party by or on behalf of Aevi, its Affiliate
or its sublicensee in such country following receipt of the applicable Regulatory Approval of such Product to Commercialize such
Product in such country.

 

2.1.35. 
   “Governmental Entity” means any applicable supra-national, federal, national, regional, state,
provincial, or local regulatory agencies, departments, bureaus, commissions, councils, or other government entities with jurisdiction
to review the substantive impact of deals on competition, including Federal Trade Commission of the United States and the United
States Department of Justice.

 

2.1.36.   
 “Hatch-Waxman Act” means the U.S. Drug Price Competition and Patent Term Restoration Act, as
amended from time to time.

 

2.1.37.   
“HSR” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

 

2.1.38. 
  “Improvements” means any and all ideas, information, Know-How, data research results, writings,
inventions, discoveries, modifications, enhancements, derivatives, new uses, developments, techniques, materials, compounds, products,
designs, processes or other technology or intellectual property, whether or not patentable or copyrightable, and all Patent Rights
and other intellectual property rights in any of the foregoing.

 

2.1.39. 
   “IND” means an Investigational New Drug Application, as defined in the FD&C Act, or similar
application or submission that is required to be filed with any Regulatory Authority before beginning clinical testing of the Molecule
or a Product in human subjects.

 

2.1.40.   
“Indirect Taxes” means value added, sales, consumption, goods and services taxes or other similar
taxes required by Applicable Law to be disclosed as a separate item on the relevant invoice.

 

2.1.41. 
   “Initiation” means the administration of the first dose of a Product to a human being in a POC
Study or a Phase 2b/3 Clinical Trial, as applicable, for which Aevi or one of its Related Parties is the sponsor.

 

2.1.42.   
“Know-How” means any non-public, proprietary invention, discovery, process, method, composition,
formula, procedure, protocol, technique, result of experimentation or testing, information, data, trade secret, material, drawings,
illustrations or other artwork, technology or other know-how, whether or not patentable or copyrightable.

 

    	 	-6-	 

     

    

 

2.1.43.   
“Manufacturing” means, as applicable, all activities associated with the production, manufacture,
processing, filling, finishing, packaging, labeling, shipping, and storage of the Molecule or Products, including process and formulation
development, process validation, stability testing, manufacturing scale-up, pre-clinical, clinical and commercial manufacture and
analytical development, product characterization, quality assurance and quality control, whether such activities are conducted
by a Party, its Affiliates or a Third Party contractor of such Party. When used as a verb, “Manufacture”
means to engage in Manufacturing.

 

2.1.44. 
  “MedImmune Excluded IP” means certain patents and know-how relating to MedImmune’s Manufacturing
and trade secrets including proprietary media and feed information related to the Molecule.

 

2.1.45. 
    “MedImmune Intellectual Property” means MedImmune Know-How and MedImmune Patent Rights, collectively.

 

2.1.46. 
   “MedImmune Know-How” means the Know-How listed on Schedule 2.1.46 and the MedImmune Documentation.

 

2.1.47. 
  “MedImmune Patent Rights” means the Patent Rights listed on Schedule 2.1.47.

 

2.1.48. 
   “Molecule” means the fully human anti-IL-18 monoclonal antibody known at MedImmune as MEDI2338.

 

2.1.49.   
“Net Sales” means, with respect to a Product for any period, the gross amount billed or invoiced
by Aevi, its Affiliates or its or their sublicensees (including distributors of authorized generic versions of the Product(s))
to Third Parties for the sale of a Product (the “Invoiced Sales”), less deductions for:

 

(a)               
normal and customary trade, quantity and prompt settlement discounts (including chargebacks and allowances) actually allowed;

 

(b)              
amounts repaid or credited by reason of rejection, return or recall of goods, rebates or bona fide price reductions;

 

(c)               
freight, postage, shipping and insurance expenses to the extent that such items are included in the gross amount invoiced;

 

 

(d)              
customs and excise duties and other taxes or duties related to the sales to the extent that such items are included in the
gross amount invoiced;

 

(e)               
rebates and similar payments made with respect to sales paid for by any governmental or regulatory authority such as, by
way of illustration and not in limitation of the Parties’ rights hereunder, Federal or state Medicaid, Medicare or similar
state program or equivalent foreign governmental program;

 

    	 	-7-	 

     

    

 

(f)               
the portion of administrative fees paid during the relevant time period to group purchasing organizations or pharmaceutical
benefit managers relating to such Product;

 

(g)              
any actual bad debt expense recorded in accordance with the Accounting Standards from customers related to sales of a Product,
such bad debt not to exceed (***) (***%***) of the total Invoiced Sales less the deductions set forth above in 2.1.44 (a) to (f).
If any bad debt is subsequently recovered, it shall be included as Net Sales.

 

Any of the deductions listed above that
involves a payment by Aevi, its Affiliates or its or their sublicensees shall be taken as a deduction in the Contract Quarter in
which the payment is accrued by such entity. For purposes of determining Net Sales, a Product shall be deemed to be sold when invoiced
and a “sale” shall not include transfers or dispositions of such Product for pre-clinical or clinical purposes or as
samples, in each case, without charge. Aevi’s, its Affiliates’ or its or their sublicensees’ transfer of any
Product to an Affiliate or sublicensee shall not result in any Net Sales, unless such Product is consumed or administered by such
Affiliate or sublicensee in the course of its commercial activities. With respect to any Product that is consumed or administered
by Aevi or its Affiliates or its or their sublicensees, Net Sales shall include any amount billed or invoiced with respect to such
consumption or administration, including any services provided in connection therewith.

 

In the event that a Product is sold in
any country in the form of a Combination Product, Net Sales of such Combination Product shall be adjusted by multiplying actual
Net Sales of such Combination Product in such country calculated pursuant to the foregoing definition of “Net Sales”
by the fraction A/(A+B), where A is the average invoice price in such country of any Product that contains the same Molecule as
such Combination Product as its sole active ingredient(s), if sold separately in such country and B is the average invoice price
in such country of each product that contains active ingredient(s) other than the Molecule(s) contained in such Combination Product
as its sole active ingredient(s), if sold separately in such country; provided that the invoice price in a country for each Product
that contains only the Molecule and each product that contains solely active ingredient(s) other than the Molecule(s) included
in the Combination Product shall be for a quantity comparable to that used in such Combination Product and of substantially the
same class, purity and potency. If either such Product that contains the Molecule(s) as its sole active ingredient or a product
that contains an active ingredient (other than the Product) in the Combination Product as its sole active ingredient(s) is not
sold separately in a particular country, the Parties shall negotiate in good faith a reasonable adjustment to Net Sales in such
country that takes into account the medical contribution to the Combination Product of and all other factors reasonably relevant
to the relative value of, the Molecule(s), on the one hand and all of the other active ingredient(s), collectively, on the other
hand. In the case of pharmacy incentive programs, hospital performance incentive programs, chargebacks, disease management programs,
similar programs or discounts on portfolio product offerings, all rebates, discounts and other forms of reimbursements shall be
allocated among products on the basis on which such rebates, discounts and other forms of reimbursements were actually granted
or, if such basis cannot be determined, in accordance with Aevi’s, its Affiliates’ or its or their sublicensees’
existing allocation method; provided that any such allocation to a Product shall be (i) done in accordance with Applicable Law,
including any price reporting laws, rules and regulations and (ii) subject to clause (i), in no event no greater than a pro rata
allocation, such that the portion of each of foregoing rebates, discounts and other forms of reimbursements shall not be included
as deductions from Invoiced Sales hereunder in any amount greater than the proportion of the number of units of such Product sold
by Aevi, its Affiliates or its or their sublicensees to Third Parties hereunder compared to the number of units of all the products
sold by Aevi, such Affiliates and such sublicensees to Third Parties to which such foregoing rebate, discount or other form of
reimbursement, as applicable, are granted Subject to the above, Net Sales shall be calculated in accordance with the standard internal
policies and procedures of Aevi, its Affiliates or its or their sublicensees, which must be in accordance with the Accounting Standards.

 

    	 	-8-	 

     

    

 

2.1.50. 
 “Patent Rights” means all patents (including all reissues, extensions, substitutions, confirmations,
re-registrations, re-examinations, revivals or revalidations, supplementary protection certificates and patents of addition) and
patent applications (including all provisional applications, continuations, continuations-in-part and divisions).

 

2.1.51. 
“Person” means any natural person, corporation, firm, business trust, joint venture, association,
organization, company, partnership or other business entity, or any government, or any agency or political subdivisions thereof.

 

2.1.52. 
“Phase 2b/3 Clinical Trial” means a human clinical trial of a Product in the United States that
is designed to evaluate both dosing requirements and the effectiveness of the Product for a particular indication in patients with
the disease or condition under study, as described under 21 C.F.R. §312.21 (as hereafter modified or amended).

 

2.1.53. 
“PHS Act” means the Public Health Services Act (Title 42, U.S.C., Chapter 6A). As used herein
the PHS Act will refer, more specifically, to 42 USC § 262, which governs the regulation of biological products.

 

2.1.54. 
“POC Study” means a human clinical trial of a Product in the United States that is designed to
preliminarily evaluate safety, tolerability, and short term efficacy of the Molecule or a Product for a particular indication in
patients with the disease or condition under study.

 

2.1.55. 
“Product” means a product containing the Molecule, alone or in combination with one or more other
active pharmaceutical ingredients.

 

2.1.56. 
“Product Trademarks” means the trademark(s), service mark(s), accompanying logos, trade dress
and/or indicia of origin used in connection with the distribution, marketing, promotion and Commercialization of any Product in
a country in the Territory. For purposes of clarity, the term Product Trademark(s) shall not include the corporate names and logos
of either Party or their Affiliates, or sublicensee(s).

 

2.1.57. 
“Regulatory Approval” means the approval of the applicable Regulatory Authority necessary for
the testing, commercial manufacture, distribution, marketing, promotion, offer for sale, use, import, export and sale of a Product
in a country in the Territory, including, where required, separate pricing and/or reimbursement approvals.

 

    	 	-9-	 

     

    

 

2.1.58. 
“Regulatory Approval Application” means an application submitted to the appropriate Regulatory
Authority seeking Regulatory Approval of a Product in a country in the Territory, including, without limitation, INDs and BLAs.

 

2.1.59. 
“Regulatory Authority” means any applicable supranational, national, regional, state or local
regulatory agency, department, bureau, commission, council or other government entity involved in granting of Regulatory Approval
for a Product in a jurisdiction within the Territory, including, without limitation, the FDA.

 

2.1.60. 
“Regulatory Exclusivity” means, with respect to a Product, that Third Parties are prevented from
legally developing, manufacturing or commercializing a product that could compete with such Product in a country, either through
data exclusivity rights, orphan drug designation, or such other rights conferred by a Regulatory Authority in such country, other
than through Patent Rights.

 

2.1.61. 
“Regulatory Materials” means regulatory applications, submissions, notifications, communications,
correspondence, registrations, Regulatory Approvals and/or other filings made to, received from or otherwise conducted with a Regulatory
Authority that are necessary in order to Develop, Manufacture, or Commercialize any Product in a country in the Territory.

 

2.1.62. 
“Related Party” means Aevi’s Affiliates and permitted sublicensees.

 

2.1.63. 
“Royalty Term” means, on a country-by-country basis, the period of time commencing on the date
of the First Commercial Sale of the first Product in such country and extending until the later of (a) (***) from the date of the
First Commercial Sale of such Product in such country; (b) the expiration in such country of the last Valid Claim of the last to
expire MedImmune Patent Rights or (c) expiration of Regulatory Exclusivity in such country.

 

2.1.64. 
 “Territory” means worldwide.

 

2.1.65. 
“Third Party” means any Person other than a Party or any of its Affiliates.

 

2.1.66. 
“Valid Claim” means any claim in an issued and unexpired patent within the MedImmune Patent Rights
which has not been disclaimed, abandoned, revoked, or held unenforceable, unpatentable or invalid by a governmental agency or competent
court.

 

    	 	-10-	 

     

    

 

2.2.          Additional Definitions. The following terms have the meanings set forth in the corresponding Sections of this Agreement:

 

	Defined Term	 	Section Reference
	“Accredited Investor”	 	11.2.7
	“Action”	 	12.2.1
	“Aevi”	 	Preamble
	“Aevi Indemnitees”	 	11.6.2
	“Agreement”	 	Preamble
	“Agreement Effective Date”	 	Preamble
	“Antibody Material”	 	4.2
	“Anti-Bribery Laws”	 	11.1.5
	“Audited Party”	 	7.6.2
	“Blocking Patent Claims”	 	8.5.3(a)
	“BPCIA”	 	8.4.2
	“Breaching Party”	 	10.2.1
	“Cell Line”	 	4.3
	“Clinical Material”	 	4.2
	“CMO”	 	10.4.1
	“Common Stock”	 	7.1.2
	“Deadline”	 	1.2
	“Development Progress Notice”	 	5.1.2
	“Date of Notice”	 	10.2.1
	“Disclosing Party”	 	9.1
	“Election Notice”	 	1.2
	“First BLA”	 	7.2
	“First MAA”	 	7.2
	“embodiments of intellectual property”	 	10.5
	“Indemnitee”	 	11.6.3
	“Indication”	 	5.1.3
	“Infringement Claim”	 	8.5.1
	“Infringement Defense Costs”	 	8.5.3(d)
	“IP”	 	10.5
	“License Effective Date”	 	1.2
	“Losses”	 	11.6.1
	“MedImmune Documentation”	 	4.1
	“MedImmune Indemnitees”	 	11.6.1
	“MedImmune”	 	Preamble
	“Milestone Event”	 	7.2
	“Milestone Payment”	 	7.2
	“Party”	 	Preamble
	“Parties”	 	Preamble
	“Patent Challenge”	 	8.2.2
	“Product Candidate”	 	5.1.3
	“Public Filings”	 	11.2.8
	“Receiving Party”	 	9.1
	“SEC”	 	7.1.3
	“Section 351(k) Applicant”	 	8.4.1
	“Securities Act”	 	7.1.3
	“Shares”	 	7.1.2
	“Term”	 	10.1
	“Third Party Claim”	 	11.6.1

 

    	 	-11-	 

     

    

 

Article
3 

LICENSES AND INTELLECTUAL PROPERTY OWNERSHIP

 

3.1.          License Grant. Subject to the terms and conditions of this Agreement, MedImmune hereby grants Aevi an exclusive (even
as to MedImmune) worldwide license, with the right to sublicense as provided in Section 3.2, the MedImmune Intellectual Property
to Develop, have Developed, Manufacture, have Manufactured, Commercialize and have Commercialized the Molecule and Products in
the Field in the Territory.

 

3.2.          Sublicenses.

 

3.2.1.     
Right to Sublicense. Aevi may sublicense the rights granted to it under Section 3.1 to one or more of its Affiliates
or Third Parties at any time. Aevi shall remain responsible for the performance of its sublicensees under this Agreement, including
for all payments due hereunder, whether or not such payments are made by Aevi, its Affiliates or its sublicensees. Aevi shall notify
MedImmune of any sublicense within five (5) Business Days of the grant of the sublicense.

 

3.2.2.     
Terms. Each sublicense granted by Aevi under this Agreement shall be subject and subordinate to the terms and conditions
of this Agreement and shall contain terms and conditions consistent with those in this Agreement including, in the case of agreements
with any commercializing sublicensee the following provisions: (a) a requirement that such sublicensee submit applicable sales
or other reports consistent with those required hereunder; (b) an audit requirement similar to the requirement set forth in Section
7.6; and (c) a requirement that such sublicensee comply with the confidentiality and non-use provisions of Article 9 with respect
to both Parties’ Confidential Information. Notwithstanding any sublicense, Aevi shall remain at all times fully liable for
its obligations under this Agreement.

 

3.2.3.     
Effect of Termination on Sublicenses. If this Agreement terminates for any reason, Aevi shall use its Commercially
Reasonable Efforts to assign to MedImmune or its designee and MedImmune shall use Commercially Reasonable Efforts to assume Aevi’s
rights, obligations, and interest under and in any agreement it has with a sublicensee from the effective date of such termination;
provided, however, that such sublicensee is not in breach of its sublicense agreement and such sublicensee agrees to comply with
all of the terms of this Agreement to the extent applicable from the rights originally sublicensed to it by Aevi; and provided,
further, that: (a) MedImmune shall not be liable for, and shall be indemnified and held harmless by Aevi against, any and all liability
of Aevi arising under the sublicense agreement prior to the effective date of such termination; and (b) Aevi shall not be liable
for, and shall be indemnified and held harmless by MedImmune against, any and all liability arising under the sublicense agreement
on or after the effective date of such termination.

 

3.3.          Ownership of and Rights to Intellectual Property.

 

3.3.1.     
Aevi Intellectual Property. Aevi is and shall remain the sole owner of the Aevi Intellectual Property.

 

    	 	-12-	 

     

    

 

 

3.3.2.     
MedImmune Intellectual Property. MedImmune is and shall remain the sole owner of the MedImmune Intellectual Property.

 

3.4.          MedImmune Covenant to Aevi. MedImmune covenants not to sue Aevi, its Affiliates, its sublicensees and the respective
successors and assigns of each of the foregoing for infringement (whether direct, contributory, inducement or otherwise) of any
Patent Rights Controlled by any of MedImmune or its Affiliates (including the Patent Rights within the MedImmune Excluded IP) arising
out of the Development, Manufacture or Commercialization of the Molecule or a Product by or on behalf of Aevi, its Affiliates,
its sublicensees and the respective successors and assigns during the Term. MedImmune shall cause its Affiliates and its and its
Affiliates’ respective licensees, sublicensees, successors and assigns to comply with the foregoing sentence as if each of
them were MedImmune.

 

3.5.          No Other Rights. Except as otherwise expressly provided in this Agreement, under no circumstances shall a Party,
as a result of this Agreement, obtain any ownership interest or other right in any, Know-How or Patent Rights of the other Party,
including items Controlled or developed by the other Party, or provided by the other Party to the receiving Party at any time pursuant
to this Agreement. For avoidance of doubt, the license granted under Section 3.1 does not include rights to MedImmune Intellectual
Property related to any molecules that are not the Molecule, and MedImmune or its Affiliates are not subject to any exclusivity
limitations for molecules targeting IL-18 that are not the Molecule.

 

Article
4 

TECHNOLOGY TRANSFER

 

4.1.          Technology Transfer. To the extent not previously provided to Aevi as of the License Effective Date, MedImmune shall
provide to Aevi copies of all documentation that: (a) Aevi reasonably requests; (b) MedImmune is able to readily locate; and (c)
is reasonably necessary to support Aevi’s Regulatory Approval Applications (“MedImmune Documentation”)
as well as all MedImmune Know-How; provided the foregoing shall not be construed so as to require MedImmune to provide any MedImmune
Excluded IP. With respect to MedImmune Documentation provided to Aevi under this Section 4.1, MedImmune may invoice Aevi at the
rate of (***$***) per hour for the time spent locating and preparing such MedImmune Documentation for transfer to Aevi, and Aevi
shall pay such invoice within thirty (30) days after receipt of the MedImmune Documentation and MedImmune’s invoice. Aevi
acknowledges that due to MedImmune’s inactivity with the Molecule there may be very limited or no further MedImmune Documentation
which MedImmune is able to provide or readily locate. There shall be no further technology transfer assistance provided to Aevi
by MedImmune or any of its Affiliates with respect to requests made by Aevi (***) after the License Effective Date except that
at Aevi’s request, MedImmune shall provide Regulatory Authorities with access to MedImmune Excluded IP if necessary for Aevi
to receive approval of a Regulatory Approval Application.

 

4.2.          Antibody Material and Clinical Material. Promptly after the request of Aevi, but no sooner than the License Effective
Date and no later than two (2) months after the License Effective Date, MedImmune or its designee shall deliver to Aevi or its
designee the quantities of the Molecule in the form set forth on Schedule 4.2 (the “Antibody Material”)
and any remaining clinical material of the Molecule in the possession of MedImmune (if any) (“Clinical Material”)
at no charge to Aevi other than packing and transportation. Such delivery shall be FCA (Incoterms 2010) MedImmune’s place
of shipment. Aevi shall pay MedImmune’s invoice for packing and transportation costs within thirty (30) days after receipt
of the Antibody Material and MedImmune’s invoice. Within sixty (60) days of the License Effective Date the Parties will negotiate
and enter into a quality assurance agreement. For clarity, Aevi acknowledges and agrees that MedImmune shall be under no obligation
to manufacture any additional Antibody Material.

 

    	 	-13-	 

     

    

 

4.3.          Cell Line. Promptly after the request of Aevi, but no sooner than the License Effective Date and no later than two
(2) months after the License Effective Date, MedImmune or its designee shall deliver to Aevi or its designee the quantity of frozen
vials of the cell line used to express the Molecule (“Cell Line”) set forth on Schedule 4.3 at
no charge to Aevi other than packing and transportation. Such delivery shall be FCA (Incoterms 2010) MedImmune’s place of
shipment. Aevi shall pay MedImmune’s invoice for packing and transportation costs within thirty (30) days after receipt of
the Cell Line and MedImmune’s invoice. For clarity, Aevi acknowledges and agrees that MedImmune shall be under no obligation
to provide any additional quantities of the Cell Line.

 

4.4.          Disclaimers. EXCEPT FOR THE IMPLIED WARRANTY OF TITLE, MEDIMMUNE PROVIDES THE ANTIBODY MATERIAL, CLINICAL MATERIAL
AND CELL LINE “AS-IS”, AND MEDIMMUNE DISCLAIMS ANY AND ALL IMPLIED WARRANTIES (OTHER THAN THE IMPLIED WARRANTY OF TITLE)
CONCERNING THE ANTIBODY MATERIAL, CLINICAL MATERIAL AND CELL LINE INCLUDING WARRANTIES CONCERNING THE QUALITY, CONDITION, EFFICACY,
SAFETY OR UTILITY OF THE ANTIBODY MATERIAL, CLINICAL MATERIAL AND THE CELL LINE INCLUDING IMPLIED WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT. For the avoidance of doubt, except as otherwise provided in this Agreement,
Aevi has no liability to MedImmune for any loss or casualty of the Antibody Material, Clinical Material and/or Cell Line or obligation
to reimburse MedImmune for any such loss or casualty or Aevi’s use of quantities of the Antibody Material, Clinical Material
and/or Cell Line and MedImmune has no liability for any claims, losses or casualty arising from Aevi’s use of the Antibody
Material, Clinical Material, and/or the Cell Line.

 

Article
5 

DEVELOPMENT, MANUFACTURE AND RELATED DILIGENCE

 

5.1.          Development. 

 

5.1.1.     
Responsibility. Aevi is solely responsible for all Development and regulatory activities, and the expenses related
thereto, with respect to the Development of the Molecule and the Product(s) in the Field in the Territory.

 

5.1.2.     
POC Studies. Aevi shall conduct one or more POC Studies in one or more indications selected by Aevi using the Antibody
Material, as requalified by Aevi at its sole cost and expense. Within thirty (30) days after completion of each POC Study, Aevi
shall notify Medimmune in writing as to whether Aevi plans to progress a Product into further clinical Development in the indication
that was the subject of the just completed POC Study (each, a “Development Progress Notice”) or conduct
another POC Study for another indication.

 

    	 	-14-	 

     

    

 

5.1.3.     
Diligence in Development. With respect to each Product that is the subject of a Development Progress Notice (each,
a “Product Candidate”) and its related indication (each, an “Indication”), Aevi shall use Commercially
Reasonable Efforts to Develop such Product Candidate in such Indication for Commercialization in the United States, the EU5 and
Canada. Aevi shall provide MedImmune a written update regarding Aevi’s development activities hereunder with respect to the
licensed Molecule upon MedImmune’s reasonable request,

 

5.2.          Specific Development Responsibilities.

 

5.2.1.     
Clinical Development. Without limiting Aevi’s obligations under Section 5.1.3, with respect to each Product
Candidate and Indication, Aevi shall develop, a clinical development strategy for the United States, the EU5 and Canada.

 

5.2.2.     
Manufacturing. Aevi is solely responsible for the Manufacture of the Molecule and each Product Candidate in the Field
in the Territory for clinical Development purposes. To the extent not included in the MedImmune Know-How, Aevi is solely responsible
for generating necessary CMC data on the Molecule and each Product Candidate for regulatory filings, including any Regulatory Approval
Application.

 

5.2.3.     
Regulatory Strategy. Without limiting Aevi’s obligations under Section 5.1.3, with respect to each Product
Candidate and Indication, Aevi shall develop a regulatory strategy for the countries in the United States, the EU5 and Canada,
including the strategy for preparation and submission of the required IND and clinical protocols thereunder and, if Development
is successful, a BLA for the Product Candidate in the applicable Indication. With respect to each Product Candidate and Product,
Aevi and its Related Parties are solely responsible for all interactions and communications with Regulatory Authorities including,
without limitation, in relation to INDs, BLAs, label development, advisory committee meetings or their equivalent (if applicable)
and negotiation with Regulatory Authorities regarding post-approval requirements/commitments.

 

5.2.4.     
Regulatory Approvals. All Regulatory Approval Applications and Regulatory Approvals shall be owned by Aevi or its
Related Party.

 

5.2.5.     
Records. Aevi shall maintain written scientific records of Development in reasonable detail consistent with Aevi's
record keeping for its other products.

 

5.3.          Third Parties. Aevi and its Related Parties shall be entitled to utilize the services of Third Parties, including
Third Party contract research organizations and service providers to perform their respective Development activities; provided,
however, that Aevi shall remain at all times fully liable for its responsibilities under this Agreement. Any agreement with a Third
Party to perform Aevi’s Development obligations under this Agreement shall be consistent with Aevi’s obligations under
this Agreement including confidentiality and non-use provisions which are no less stringent than those set forth in Article 9.

 

    	 	-15-	 

     

    

 

Article
6 

COMMERCIALIZATION AND RELATED DILIGENCE

 

6.1.          Diligence in Commercialization. With respect to each Product that receives Regulatory Approval in the United States,
the EU5 or Canada Aevi, through itself and its Related Parties, shall use Commercially Reasonable Efforts to Commercialize such
Product in the applicable Indication in such country.

 

6.2.          Commercialization. Aevi is solely responsible for all, and, as between MedImmune and Aevi, shall record all top line
revenues in connection with, Commercialization activities relating to Products in the Field in the Territory.

 

6.3.          Commercial Manufacturing and Supply. Aevi is solely responsible for the Manufacture of the Molecule and each Product
for commercial purposes in the Field in the Territory.

 

6.4.          Medical and Scientific Affairs. Aevi is solely responsible for medical and scientific affairs and programs, including
professional symposia and other educational activities with respect to each Product in the Field in the Territory. Aevi shall have
the exclusive right to respond to all questions or requests for information about the Products made by any medical professionals
or any other Person in Field in the Territory.

 

Article
7 

FINANCIAL PROVISIONS

 

7.1.          Licensee
Fees. 

 

7.1.1.     
Cash Payment. Within five (5) Business Days following the License Effective Date, Aevi shall pay MedImmune an amount
equal to (***) (***$***) by wire transfer of immediately available and cleared funds pursuant to wire transfer instructions provided
by MedImmune in writing.

 

7.1.2.     
Issuance of Aevi Common Stock. Within five (5) Business Days following the License Effective Date, Aevi shall issue
to MedImmune shares of fully-paid and non-assessable Common Stock,
in an amount calculated by dividing (i) (***) (***$***) by (ii) the average of the closing price per share of Common Stock for
each of the (***) trading days ending on the License Effective Date, as reported by the Nasdaq Stock Market (the “Shares”)
(or if the Common Stock is not then traded on the Nasdaq Stock Market, then as reported by the national securities exchange, over-the-counter
market or other securities trading platform on which the Common Stock is then listed or traded and for which transactions in the
Common Stock are regularly reported); provided that if the issuance of the Shares would result in MedImmune owning greater
than 19.9% of Aevi’s then issued and outstanding Common Stock (after giving effect to the issuance of, and including, the
Shares), then MedImmune shall receive shares of Common Stock such that MedImmune would own shares of Common Stock not in excess
of 19.9% of the then issued and outstanding shares of Common Stock, with the balance of the Shares otherwise payable hereunder
to be paid by Aevi in cash.

 

    	 	-16-	 

     

    

 

7.1.3.     
Registration of Shares. At its sole expense, Aevi shall prepare and file with the Securities and Exchange Commission
(the “SEC”) a resale registration statement on Form S-3 under the Securities Act of 1933, as amended
(the “Securities Act”) (it being agreed that such registration statement shall be a registration statement
filed for an offering to be made on a delayed or continuous basis pursuant to Rule 415 under the Securities Act (or any successor
rule), including any post-effective amendment thereto, if then available to Aevi, and if Form S-3 is not then available to Aevi,
such resale registration statement shall be on Form S-1 or any similar or successor form under the Securities Act (the registration
statement filed pursuant to this Section 7.1.3 being referred to as the “Registration Statement”)) for
the resale of all or part of the Shares. Aevi shall file the Registration Statement as promptly as practicable following the License
Effective Date, but in no event later than the thirtieth (30th) calendar day following the License Effective Date provided,
however, that if such date is not a Business Day or is such other day that the SEC is closed for business, the date by which
such Registration Statement shall be filed shall be extended to the next Business Day on which the SEC is open for business. Such
registration statement shall be in the form of a customary resale registration statement and shall include a plan of distribution
permitting MedImmune to sell the Shares by any method legally available (including direct sales to purchasers, a sale to or through
brokers, dealers or agents, a sale over the internet, block sales, derivative transactions with third parties, sales in connection
with short sales and other hedging transactions). Aevi shall afford MedImmune reasonable opportunity to review and provide comments
on a draft of the Registration Statement prior to filing. After the filing of the Registration Statement, Aevi shall use Commercially
Reasonable Efforts to cause the Registration Statement to be declared effective by the SEC staff as soon as practicable, but in
no event later than the sixtieth (60th) calendar day following the License Effective Date (or the ninetieth (90th)
calendar day following the License Effective Date in the event of a full review by the SEC); provided, however, that if
Aevi is notified by the SEC that the Registration Statement will not be reviewed or is no longer subject to further review and
comments, the date by which such Registration Statement shall be declared effective by the SEC staff shall be the fifth (5th)
Business Day following the date on which Aevi is so notified if such date precedes the dates otherwise required above; provided,
further, that if any such date is not a Business Day or is such other day that the SEC is closed for business, the date by
which such Registration Statement shall be declared effective by the SEC staff shall be extended to the next Business Day on which
the SEC is open for business. Thereafter, Aevi shall use Commercially Reasonable Efforts to keep such Registration Statement continuously
effective, including by filing any necessary post-effective amendments to such Registration Statement or a new registration statement
until the earlier of (a) the date on which all of the Shares have been sold, either pursuant to such Registration Statement or
any successor registration statement filed under the Securities Act, (but in no event prior to the applicable period referred to
in Section 4(a)(3) of the Securities Act and Rule 174 thereunder) or pursuant to Rule 144 or other exemption from registration
under the Securities Act, (b) such time as none of the Shares are outstanding, and (c) such time as all Shares owned by MedImmune
are able to be sold by MedImmune without restriction as to volume or manner of sale pursuant to Rule 144 under the Securities Act;
provided that, in the case of clause (c), Aevi has delivered an opinion of counsel reasonably satisfactory to the transfer agent
for the Common Stock to such effect. Aevi shall use Commercially Reasonable Efforts to cooperate with MedImmune in any sales of
Shares pursuant to the Registration Statement, and shall amend or supplement the Registration Statement or prospectus relating
to such Registration Statement as may be reasonably requested by MedImmune, or as may be necessary to keep such Registration Statement
effective and to comply with the provisions of the Securities Act with respect to the disposition of all Shares, for so long as
MedImmune owns any Shares. Further, Aevi shall file all reports required to be filed by it under the Securities Exchange Act of
1934, as amended, (the “Exchange Act”) and the SEC’s rules and regulations thereunder, and will
take such further action as MedImmune may reasonably request, to the extent required to enable MedImmune to sell Shares without
registration under the Securities Act in accordance with Rule 144. Aevi shall use Commercially Reasonable Efforts to cause the
Shares to be listed on the Nasdaq Global Market or such other national securities exchange on which the Common Stock is then listed.
For the avoidance of doubt, Aevi will not be deemed to have breached its obligation to use Commercially Reasonable Efforts to cause
the Shares to be listed on the Nasdaq Global Market in the event that its Common Stock is delisted from the Nasdaq Global Market.

 

    	 	-17-	 

     

    

 

7.2.         
Milestones. In consideration of the license granted to Aevi pursuant to Section 3.1, Aevi shall make the following
one time milestone payments to MedImmune (each, a “Milestone Payment”) no later than thirty (30) days
after the end of the Contract Quarter in which Aevi or any of its Related Parties achieve the corresponding milestone event (each,
a “Milestone Event”):

 

	Development Milestone	 	Payment
	(***)	 	(***$***)
	(***)	 	(***$***)
	(***)	 	(***$***)
	(***)	 	(***$***)
	(***)	 	(***$***)
	Total Development Milestones	 	(***$***)

 

 

	Sales Related Milestones	 	Payment
	Annual Net Sales ≥ (***$***)	 	(***$***)
	Annual Net Sales ≥ (***$***)	 	(***$***)
	Annual Net Sales ≥ (***$***)	 	(***$***)
	Annual Net Sales ≥ (***$***)	 	(***$***)
	Total Sales Related Milestones	 	(***$***)

 

Once Aevi has made any particular Milestone
Payment under this Section 7.2, Aevi shall not be obligated to make any payment under this Section 7.2 with respect to the re-occurrence
of the same Milestone Event, whether or not such re-occurrence is with respect to a different or the same Product.

 

    	 	-18-	 

     

    

 

7.3.          Royalties.

 

7.3.1.     
Full Royalty Rate. Aevi shall pay MedImmune royalties as a percentage of aggregate Annual Net Sales generated in
each country of sale of the Products in the Territory during the period in which a Valid Claim or Regulatory Exclusivity exists
in such country at the applicable rates set forth below:

 

	Increment of Annual Net Sales	 	Royalty Rate
	Less than (***$***)	 	(***%***)
	≥ (***$***)	 	(***%***)

 

7.3.2.     
Reduced Royalty Rate. Aevi shall pay MedImmune royalties as a percentage of aggregate Annual Net Sales generated
in each country of sale of the Products in the Territory during the period in which no Valid Claim or Regulatory Exclusivity exists
in such country or in which a Biosimilar is commercialized in such country at (***%***) of the rates set forth in the table in
Section 7.3.1.

 

7.3.3.     
Expiration of Royalty. The obligation to pay royalty under Section 7.3 shall expire on a country-by-country basis
upon the expiration of the Royalty Term in such country.

 

7.4.          Reports and Royalty Payments. Within sixty (60) days after the end of each Contract Quarter commencing in the Contract
Quarter immediately following the Contract Quarter in which there was the First Commercial Sale of any Product, Aevi shall deliver
to MedImmune a report setting forth for the previous Contract Quarter the following information on a Product-by- Product basis:
(a) the gross sales and Net Sales of each Product, (b) the number of units sold by Aevi and its Related Parties, (c) the royalty
due hereunder, (d) the applicable exchange rate as determined pursuant to Section 7.5.5; and (e) the calculation of any true-up
required with respect Net Sales reported and payments made in connection with prior Contract Quarter(s). The total royalty due
to MedImmune for the sale of Products during such Contract Quarter shall be remitted at the time such report is made.

 

7.5.          Payment Provisions Generally.

 

7.5.1.     
Taxes and Withholding. All amounts payable under this Agreement shall be paid free and clear of any and all taxes,
except for any withholding taxes required by Applicable Law. Except as provided in this Section 7.5, each Party shall be solely
responsible for paying any and all taxes (other than withholding taxes required by Applicable Law to be deducted from payments
and remitted by the other Party) levied on account of, or measured in whole or in part by reference to, any payments it receives.
Each Party shall deduct or withhold from the payments any taxes that it is required by Applicable Law to deduct or withhold. Notwithstanding
the foregoing, if a Party is entitled under any applicable tax treaty to a reduction of rate of, or the elimination of, applicable
withholding tax, it may deliver to the other Party or the appropriate governmental authority (with the assistance of the other
Party to the extent that this is reasonably required and is requested in writing) the prescribed forms necessary to reduce the
applicable rate of withholding or to relieve such Party of its obligation to withhold such tax and that Party shall apply the reduced
rate of withholding or dispense with withholding, as the case may be; provided that a Party has received evidence of the other
Party’s delivery of all applicable forms (and, if necessary, its receipt of appropriate governmental authorization) at least
fifteen (15) days prior to the time the payments are due. If, in accordance with the foregoing, a Party withholds any amount, it
shall make timely payment to the proper taxing authority of the withheld amount and send to the other Party proof of such payment
within ten (10) days following such payment.

 

    	 	-19-	 

     

    

 

7.5.2.     
Gross Up. If the paying Party transfers (whether by way of legal or equitable assignment, declaration of trust, novation
or otherwise) the benefit in whole or in part of this Agreement or, after the Agreement Effective Date, changes its tax residence
or the permanent establishment to which the rights under the Agreement are allocated and. a payment under this Agreement is subject
to withholding tax where the payment would not have been subject to withholding tax or would have been subject to a lower rate
of withholding tax in the absence of such transfer, change in tax residence or permanent establishment, then the paying Party or
its assignee (as the case may be) shall be obliged to pay to the recipient such sum as will after such deduction or withholding
has been made leave the recipient with the same amount as it would have been entitled to receive had no transfer, change in tax
residence or permanent establishment taken place.

 

7.5.3.     
Anti-Tax Evasion. (a) Each of Aevi and MedImmune represents, warrants and undertakes that it nor its Affiliates shall
commit a UK tax evasion facilitation offence under section 45(5) of the UK Criminal Finances Act 2017 in connection with or attributable
to this Agreement or the transactions contemplated hereby, (b) each Party shall promptly report to the other Party any apparent
breach of Section 7.5.3(a) and shall (i) answer, in reasonable detail, any written or oral inquiry from the other Party related
to its and its Affiliates compliance with Section 7.5.3(a), (ii) facilitate the interview of employees of such Party by the other
Party (or any agent of such Party) at any reasonable time specified by
the inquiring Party related to such Party’s compliance with Section 7.5.3(a) and (iii) co-operate with the inquiring
Party and/or any governmental authority in relation to any investigation relating to the matters referred to in Section 7.5.3(a),
in all cases, as reasonably required to enable that other Party to comply with its undertaking in Section 7.5.3(a).

 

7.5.4.     
Indirect Taxes. Notwithstanding anything to the contrary contained in this Section 7.5.4 or elsewhere in this Agreement,
the following shall apply with respect to Indirect Taxes. All payments are stated exclusive of Indirect Taxes. If any Indirect
Taxes are chargeable in respect of any payments, the payer shall pay such Indirect Taxes as the applicable rate in respect of any
such payments, following the receipt, where applicable, of an Indirect Taxes invoice issued in the appropriate form by the payee
in respect of those payments to which such Indirect Taxes relate. The Parties shall issue invoices for all goods and services supplied
under this Agreement consistent with Indirect Tax requirements, and to the extent any invoice is not initially issued in an appropriate
form, the parties shall cooperate to provide such information or assistance as may be necessary to enable the issuance of such
invoice consistent with Indirect Tax requirements. MedImmune acknowledges that based on current Applicable Law, MedImmune does
not intend to invoice Aevi for value added taxes in respect of the transactions effected by this Agreement.

 

7.5.5.     
Payment and Currency Exchange. All amounts payable and calculations hereunder shall be in United States dollars and
shall be paid by bank wire transfer in immediately available and cleared funds to such bank account as may be designated in writing
by MedImmune from time to time. Whenever for the purposes of calculating royalties payable under this Agreement, conversion from
any foreign currency will be required, all amounts will first be calculated in the currency in which the activity was paid or sale
was recorded and then converted into United States dollars equivalent using its, its Affiliates or sublicensee’s, as applicable,
standard conversion methodology consistent with the relevant applicable Accounting Standards. All payments will be non-refundable
and not creditable once received by MedImmune except for any applicable accounting true-ups.

 

    	 	-20-	 

     

    

 

7.5.6.     
Overdue Payments. If any payment due to either Party under this Agreement is not paid when due, then such paying
Party shall pay interest thereon (before and after any judgment) at an annual rate (but with interest compounding on a daily basis)
of nine hundred (900) basis points above the U.S. effective federal funds rate, as adjusted each Business Day and published by
the Federal Reserve Bank of New York through its website (https://apps.newyorkfed,org/markets/autorates/fed%20funds) (or
in the event that U.S. effective federal funds rate is no longer an applicable reference rate, such reasonably equivalent alternative
as may be selected by MedImmune in its reasonable discretion), such interest to run from the date on which payment of such sum
became due until payment thereof in full together with such interest. Notwithstanding the previous sentence, the payable interest
rate shall never be less than nine hundred (900) basis points.

 

7.6.          Maintenance of Records; Audits.

 

7.6.1.     
Record-Keeping. Aevi shall keep, and shall cause its Related Parties to keep, books and accounts of record in connection
with the sale of Products and in sufficient detail to permit accurate determination of all figures necessary for verification of
royalties to be paid hereunder. Aevi shall maintain, and shall cause its Related Parties to maintain, such records for a period
of at least three (3) years after the end of the Contract Year in which they were generated.

 

7.6.2.     
Audits. Upon thirty (30) days’ prior written notice from MedImmune, Aevi or any of its Related Parties receiving
the written notice (the “Audited Party”) shall permit an independent certified public accounting firm
of nationally recognized standing selected by MedImmune and reasonably acceptable to the Audited Party, to examine, at MedImmune’s
sole expense, the relevant books and records of the Audited Party and its Affiliates as may be reasonably necessary to verify the
amounts reported in accordance with Section 7.4 and the payment of royalties hereunder. An examination by MedImmune under this
Section 7.6.2 shall occur not more than once in any Contract Year and shall be limited to the pertinent books and records for any
Contract Year ended not more than two (2) years before the date of the request. The accounting firm shall be provided access to
such books and records at the Audited Party’s facility(ies) where such books and records are normally kept and such examination
shall be conducted during the Audited Party’s normal business hours. The Audited Party may require the accounting firm to
sign a standard non-disclosure agreement before providing the accounting firm access to the Audited Party’s facilities or
records. Upon completion of the audit, the accounting firm shall provide Aevi, MedImmune and the Audited Party a written report
disclosing any discrepancies in the reports submitted by the Audited Party or, as applicable, the royalties paid, and in each case,
the specific details concerning any discrepancies. No other information pertaining to the Audited Party’s books and records
shall be provided to MedImmune.

 

    	 	-21-	 

     

    

 

7.6.3.     
Underpayments/Overpayments. If such accounting firm correctly concludes (such conclusion subject to the dispute resolution
procedures set forth in Section 12.17) that additional royalties were due to MedImmune, Aevi shall, if applicable, pay to MedImmune
the additional royalties within sixty (60) days after the date Aevi receives such accountant’s written report so correctly
concluding (unless disputed in good faith hereunder). If such underpayment exceeds ten percent (***%***) of the royalties that
were to be paid for all audited periods, Aevi also shall reimburse MedImmune for all out-of-pocket expenses incurred in conducting
the audit. If such accounting firm correctly concludes that Aevi overpaid royalties to MedImmune, then MedImmune shall refund such
overpayments to Aevi, within sixty (60) days after the date MedImmune receives such accountant’s report so correctly concluding.

 

7.6.4.     
Confidentiality. All financial information of an Audited Party that is subject to review under this Section 7.6 shall
be deemed to be Confidential Information of such Audited Party subject to the provisions of Article 9, and MedImmune shall not
disclose such Confidential Information to any Third Party or use such Confidential Information for any purpose other than verifying
payments to be made by Aevi to MedImmune hereunder.

 

Article
8 

INTELLECTUAL PROPERTY PROTECTION AND RELATED MATTERS

 

8.1.          Filing,
Prosecution and Maintenance of MedImmune Patent Rights. 

 

8.1.1.     
Responsibility. Subject to Section 8.1.4, Aevi through counsel to Aevi but reasonably acceptable to MedImmune shall
have primary responsibility for and control over the prosecution and maintenance of the MedImmune Patent Rights throughout the
Territory in MedImmune’s name, all at Aevi’s sole cost and expense.

 

8.1.2.     
Information Sharing; Comment. Aevi shall keep MedImmune reasonably informed of patent prosecution activities concerning
the MedImmune Patent Rights in the Territory and provide MedImmune with copies of material correspondence (including, but not limited
to, applications, office actions, responses, etc.) relating to prosecution of the MedImmune Patent Rights. MedImmune may provide
comments and suggestions with respect to any material actions to be taken by Aevi, and Aevi shall reasonably consider all comments,
suggestions and prosecution actions recommended by MedImmune.

 

8.1.3.     
Common Interest. All information exchanged between the Parties regarding preparation, filing, prosecution or maintenance
of the MedImmune Patent Rights shall be deemed Confidential Information. In addition, the Parties acknowledge and agree that, with
regard to such preparation, filing, prosecution and maintenance of the MedImmune Patent Rights, the interests of the Parties are
to obtain the strongest patent protection possible, and as such, are aligned and are legal in nature. The Parties agree and acknowledge
that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning the MedImmune
Patent Rights, including, without limitation, privilege under the common interest doctrine and similar or related doctrines. To
be clear, all information exchanged between counsel to each of the Parties regarding the preparation, filing, prosecution or maintenance
of the MedImmune Patent Rights shall be deemed Confidential Information and subject to the common interest doctrine.

 

    	 	-22-	 

     

    

 

8.1.4.     
Election Not to Continue Prosecution; Abandonment. If Aevi elects not to continue the prosecution or maintenance
of a MedImmune Patent Right in the Territory, then (a) Aevi shall so notify MedImmune promptly in writing of its intention in good
time to enable MedImmune to meet any deadlines by which an action must be taken to establish or preserve any such rights in such
patent in the Territory and (b) MedImmune shall have the right, but not the obligation, to file for, or continue to prosecute,
maintain or enforce, or otherwise pursue such MedImmune Patent Rights in the Territory, and Aevi shall cooperate with MedImmune
in regards thereto.

 

8.1.5.     
Cooperation. MedImmune shall reasonably cooperate (a) if necessary and appropriate, with Aevi in gaining patent term
extensions and the like wherever applicable to MedImmune Patent Rights; and (b) Aevi’s prosecution and maintenance of the
MedImmune Patent Rights; both (a) and (b) at Aevi’s sole cost and expense.

 

8.2.          Invalidity or Unenforceability Defenses or Actions.

 

8.2.1.     
Notices. Each Party shall promptly notify the other Party in writing of any alleged or threatened assertion of invalidity
or unenforceability of any of the MedImmune Patent Rights by a Third Party of which such Party becomes aware.

 

8.2.2.     
Response. In the event that a Third Party challenges any of the MedImmune Patent Rights, regardless of the name or
procedure including, without limitation, opposition, validity challenge, interference, re-examination, reissue, derivation, supplemental
examination, post-grant review, inter-parties review, negotiation, claim, declaratory judgment action or counterclaim or affirmative
defense in an infringement suit brought under Section 8.3 (each, a “Patent Challenge”), Aevi shall have
the first right, but not the obligation, to: (a) defend and prosecute the Patent Challenge in its own name, at its own expense
(provided that such expenses shall be treated as Infringement Defense Costs), and on its own behalf; (b) to the extent applicable
to the Patent Challenge, ultimately enjoin infringement and collect for its use, damages, profits, and awards of whatever nature
recoverable for such infringement; and (c) settle the Patent Challenge; provided, however, that MedImmune shall have the second
right, but not the obligation, to take such actions at its own expense and in its own name with respect to a Patent Challenge if
Aevi chooses not to defend and prosecute such Patent Challenge. MedImmune shall join any such Patent Challenge if necessary to
avoid dismissal of the Patent Challenge. In all cases, Aevi agrees to keep MedImmune reasonably apprised of the status and progress
of the Patent Challenge.

 

8.3.          Enforcement of Patent Rights.

 

8.3.1.     
Notification. Each Party shall promptly report in writing to the other Party during the Term any (a) known or suspected
infringement of any MedImmune Patent Rights or (b) unauthorized use or misappropriation of any Confidential Information, including
MedImmune Intellectual Property, by a Third Party of which it becomes aware, and shall provide the other Party with all available
evidence supporting such infringement or unauthorized use or misappropriation.

 

    	 	-23-	 

     

    

 

8.3.2.     
Rights to Enforce. In respect of Products in the Field in the Territory, Aevi shall have the first right, but not
the obligation, to take any reasonable measures it deems appropriate to stop infringing activities in the Field in the Territory,
including (a) initiating or prosecuting an infringement or other appropriate suit or action against, and (b) settling or ceasing
any such infringement action or other suit, including, but not limited to, granting adequate rights and licenses necessary for
continuing such activities in the Territory to any Third Party who at any time has infringed, or is suspected of infringing, any
MedImmune Patent Rights, or of using without proper authorization any MedImmune Know-How claiming or relating to the Molecule or
Products. In the event that Aevi elects not to take action pursuant to this Section 8.3.2, Aevi shall so notify MedImmune in writing
of its intention within ninety (90) days after Aevi’s notice of such infringement activities, or within such shorter time
as is necessary to enable MedImmune to meet any deadlines by which an action must be taken to establish or preserve any enforcement
rights. Thereafter, the Parties shall consult with one another in an effort to determine whether a reasonably prudent licensee
would institute litigation to enforce the MedImmune Intellectual Property in question in light of all relevant business and economic
factors (including, but not limited to, the projected cost of such litigation, the likelihood of success on the merits, the probable
amount of any damage award, the prospects for satisfaction of any judgment against the alleged infringer, the possibility of counterclaims
against the Parties or likely Patent Challenges, the impact of any possible adverse outcome on the Parties and the effect any publicity
might have on the Parties’ respective reputations and goodwill). If, after such process, it is unanimously determined that
a suit should be filed and Aevi does not file suit or commence settlement negotiations forthwith against the infringer, then MedImmune
shall have the right, at its own expense, to enforce the MedImmune Intellectual Property in question on behalf of itself and Aevi
and MedImmune shall have the right, but not the obligation, to take any such reasonable measures to stop such infringing activities
by such alleged infringer.

 

8.3.3.     
Procedures; Expenses and Recoveries. The Party having the right to initiate any infringement suit under Section 8.3.2
shall have the sole and exclusive right to select counsel for any such suit and shall pay all expenses of the suit, including attorneys’
fees and court costs and reimbursement of the other Party’s reasonable out-of-pocket expenses in rendering assistance requested
by the initiating Party. If required under Applicable Law in order for the initiating Party to initiate and/or maintain such suit,
or if either Party is unable to initiate or prosecute such suit solely in its own name, in each case, the other Party shall join
as a party to the suit and shall execute and cause its Affiliates to execute all documents necessary for the initiating Party to
initiate litigation to prosecute and maintain such action. In addition, at the initiating Party’s request, the other Party
shall provide reasonable assistance to the initiating Party in connection with an infringement suit at no charge to the initiating
Party except for reimbursement by the initiating Party for reasonable out-of-pocket expenses incurred in rendering such assistance.
The non-initiating Party shall have the right to participate and be represented in any such suit by its own counsel at its own
expense. If the Parties obtain from a Third Party, in connection with such suit, any damages, license fees, royalties or other
compensation (including any amount received in settlement of such litigation), such amounts shall be allocated as follows:

 

    	 	-24-	 

     

    

 

(a)              
in all cases, first to reimburse the initiating Party for all expenses of the suit, including attorneys’ fees and
disbursements, court costs and other litigation expenses, and then to reimburse the other Party for its reasonable attorneys’
fees and disbursements, court costs and other litigation expenses; and

 

(b)              
if Aevi is the initiating Party, any of the remaining amount that relates to the Molecule or Product shall be treated as
if it were Net Sales of Aevi, with MedImmune receiving a royalty on such remaining amount pursuant to the terms of Section 7.3,
and the balance being retained by Aevi; and

 

(c)              
if MedImmune is the initiating Party, MedImmune shall pay Aevi an amount equal to (i) the balance of any damages, license
fees, royalties or other compensation (including any amount received in settlement of such litigation) following the deductions
set forth in Section 8.3.3(a) multiplied by (ii) a fraction, the numerator of which is the reasonable attorneys’ fees and
disbursements, court costs and other litigation expenses incurred by Aevi in connection with such suit and the denominator of which
is the reasonable attorneys’ fees and disbursements, court costs and other litigation expenses incurred by Aevi and MedImmune
in connection with such suit.

 

8.4.          Biosimilar
Arrangements. 

 

8.4.1.     
Notice of Third Party Applications. In the event of a dispute or potential dispute that has not ripened into a demand,
claim or suit of the type described in Section 8.2, the same principles governing control of the resolution of the dispute, consent
to settlements of the dispute, and implementation of the settlement of the dispute (including sharing in and allocating the payment
or receipt of damages, license fees, royalties and other compensation) will apply. Notwithstanding anything herein to the contrary,
within three (3) years after Regulatory Approval is achieved with respect to a BLA for a Product in the United States (or such
shorter time as the Parties agree in the case of a Product in the United States that does not earn reference product exclusivity
under the PHS Act), the Parties shall consult as to potential strategies with respect to unexpired Patent Rights Controlled by
either Party that potentially could be asserted if an unlicensed person engaged in the making, using, offering to sell, selling,
or importing into the United States of a product described in a Biosimilar Application filed by a Third Party applicant (a “Section
351(k) Applicant”).

 

8.4.2.     
Cooperation and Enforcement. If Aevi, as the reference product sponsor of the Product within the meaning of section
351(l)(1)(A) of the PHS Act, receives notice of a Biosimilar Application filed by a Section 351(k) Applicant that references such
Licensed Product and related manufacturing information in accordance with section 351(l)(2)(A) of the PHS Act or receives a notice
of commercial marketing in accordance with section 351(l)(8)(A) of the PHS Act, then Aevi shall provide notice to MedImmune, and
the Parties shall discuss and MedImmune shall reasonably cooperate with Aevi in determining Aevi’s course of action with
regard to (a) engaging in the information exchange provisions of the Biologics Price Competition and Innovation Act of 2009, Section
351(k) of the Public Health Service Act, as may be amended, supplemented, or replaced (the “BPCIA”),
including providing a list of patents that relate to the relevant Product, (b) engaging in the patent resolution provisions of
the BPCIA, and (c) determining which patents will be the subject of immediate patent infringement action under section 351(l)(6)
of the BPCIA. In the event that the Parties do not agree with respect to the exercise of any such rights, Aevi shall make the final
determination with respect thereto, including without limitation with respect to (a), (b) and (c) above provided, however, that
MedImmune’s obligation shall be to reasonably cooperate with Aevi, and Aevi shall bear all out-of-pocket costs and expenses
in connection with the exercise of any such rights or actions. If any patent litigation commences with respect to a Biosimilar
Application filed by a Section 351(k) Applicant that references such Product, then the provisions of Section 8.3 shall thereafter
apply as if such Section 351(k) Applicant were an infringer or suspected infringer.

 

    	 	-25-	 

     

    

 

8.5.          Claimed Infringement of Third Party Rights.

 

8.5.1.     
Notice. In the event that a Third Party at any time provides written notice of a claim to, or brings an action, suit
or proceeding against, any Party, or any of such Party’s respective Affiliates or sublicensees, claiming infringement of
its Patent Rights (including with respect to a Blocking Patent) or unauthorized use or misappropriation of its Know-How, based
upon an assertion or claim arising out of the Development, Manufacture or Commercialization of the Molecule or a Product in the
Territory (“Infringement Claim”), such Party shall promptly notify the other Party of the Infringement
Claim or the commencement of such action, suit or proceeding, enclosing a copy of the Infringement Claim and all papers served.

 

8.5.2.     
Primary Right to Defend. Aevi shall have the first right, but not the obligation, to defend all Infringement Claims
brought in the Territory against either Party or any of its Affiliates or sublicensees arising out of the Development, Manufacture
or Commercialization of the Molecule or a Product in the Territory; provided that the foregoing shall not be construed to require
Aevi to defend MedImmune against a breach of MedImmune’s representations and warranties set forth herein.

 

8.5.3.     
Procedure.

 

(a)              
To the extent that (i) the Infringement Claim, whether in the form of an assertion by a Third Party or a filed litigation
(or other formal dispute resolution procedure), directly relates to a Blocking Patent or (ii) a Blocking Patent is identified (a
 “Blocking Patent Claim”), Aevi shall have the first right to control any negotiations and discussions
with the Third Party to resolve the Blocking Patent Claim in the Territory by acquiring a license under the Blocking Patent. For
the avoidance of doubt, if MedImmune acquires any rights to any Blocking Patent in the Territory, such rights shall be considered
MedImmune Intellectual Property subject to the license granted to Aevi in Section 3.1. If Aevi is unable to resolve the Blocking
Patent Claim by acquiring a license under the Blocking Patent on terms that are commercially reasonable to Aevi, in Aevi’s
discretion, then MedImmune may negotiate a license with the Third Party under the Blocking Patent in the Territory in the Field.
Any expense incurred by Aevi in connection with obtaining rights under or to a Blocking Patent including any ongoing royalties
or milestone payments shall be offset against any royalties or other payments payable under this Agreement as Infringement Defense
Costs under Section 8.5.3(d).

 

    -26-

     

    

 

(b)              
Aevi shall have the first right to control any negotiations and discussions with the Third Party to resolve the Infringement
Claim in the Territory by acquiring a license under the relevant Patents and Know-How. If Aevi is unable to resolve the Infringement
Claim by acquiring a license under the relevant Patent Rights or Know-How on terms that are commercially reasonable to Aevi, in
Aevi’s discretion and if the Infringement Claim has not been brought via litigation or other formal dispute resolution procedure,
then MedImmune may negotiate a license with the Third Party under the Patent Rights or Know-How in the Territory in the Field.
For the avoidance of doubt, if MedImmune acquires any rights to any Patent Rights or Know-How in the Territory, such rights shall
be considered MedImmune Intellectual Property subject to the license granted to Aevi in Section 3.1. Any expense incurred by Aevi
in connection with obtaining rights under or to Patent Rights or Know-How to resolve an Infringement Claim shall be offset against
any royalties or other payments payable thereunder as Infringement Defense Costs under Section 8.5.3(d).

 

(c)              
Aevi shall have the sole and exclusive right to select counsel to defend any Infringement Claim brought via litigation or
other formal dispute resolution procedure; provided that it shall consult with MedImmune with respect to selection of counsel for
such defense. Aevi shall keep MedImmune informed, and shall from time to time consult with MedImmune regarding the status of any
such claims and shall provide MedImmune with copies of all material documents filed in, and all material written communications
relating to, any suit brought in connection with such claims. MedImmune shall also have the right to participate and be represented
in any such claim or related suit, at its own expense. Aevi shall not settle any Infringement Claims that would adversely impact
any of the MedImmune Patent Rights (such as invalidation of or narrowing the scope of any claim of any of the MedImmune Patent
Rights) or purport to impose any obligations on MedImmune, without obtaining the prior written consent of MedImmune or its Affiliate,
as applicable, which consent shall not be unreasonably withheld.

 

(d)              
Except to the extent MedImmune owes an indemnification obligation to Aevi under this Agreement, all litigation costs and
expenses incurred by Aevi in connection with Infringement Claims or Patent Challenges, and all damages and settlement payments,
including any ongoing royalties or milestone payments negotiated by Aevi under Sections 8.2.2, 8.5.3(a) or 8.5.3(b), payable by
Aevi to the Third Party in respect of Infringement Claims or Patent Challenges (“Infringement Defense Costs”)
shall be borne by Aevi; provided that: (i) Aevi may deduct Infringement Defense Costs as incurred against the royalties and Milestone
Payment that become payable to MedImmune under Sections 7.2 and 7.3; but (ii) no quarterly payment of royalties or any milestone
payment shall be reduced by more than (***) (***%***) of the amount otherwise payable under this Agreement. For the avoidance of
doubt, if Aevi is unable to fully deduct Infringement Defense Costs against any royalties and Milestone Payment payable to MedImmune
because such amounts are less than the then-current balance of the Infringement Defense Costs (as a result of clause (ii) of this
Section 8.5.3(d) or otherwise), the undeducted amount(s) shall carry over to each succeeding accrual of royalties and Milestone
Payments until fully deducted.

 

8.6.           
Product Trademarks. Aevi and/or its Related Parties, as applicable, shall select and own the Product Trademarks for
each Product and shall be solely responsible for filing and maintaining the Product Trademarks in the Territory (including payment
of costs associated therewith). Aevi shall assume full responsibility, at its sole cost and expense, for any infringement of a
Product Trademark for a Product by a Third Party and any claims of infringement in the Territory of the rights of a Third Party
by the use of a Product Trademark in connection with a Product.

 

    -27-

     

    

 

8.7.           
Patent Term Extensions in the Territory. The Parties shall use reasonable efforts to obtain all available extensions
of Patent Rights (including those available under the Hatch-Waxman Act). Each Party shall execute such authorizations and other
documents and take such other actions as may be reasonably requested by the other Party to obtain such extensions. The Parties
shall cooperate with each other in gaining such extensions wherever applicable to Patent Rights. The Party first eligible to seek
extension of any such Patent Rights shall have the right to do so; provided that if the first Party has an option to extend the
patent term for only one of several patents, the first Party shall consult with the other Party before making the election. If
more than one patent is eligible for extension, the Parties shall select, in good faith, a strategy that shall maximize patent
protection and commercial value for each Product.

 

Article
9 

CONFIDENTIALITY

 

9.1.           
Confidential Information. All Confidential Information disclosed by a Party (together with its Affiliates, the “Disclosing
Party”) to the other Party (together with its Affiliates, the “Receiving Party”) before
or during the Term shall be used by the Receiving Party solely in connection with the activities contemplated by this Agreement,
shall be maintained in confidence by the Receiving Party and shall not otherwise be disclosed by the Receiving Party to any other
Person, firm, or agency, governmental or private (other than a Party’s Affiliates), without the prior written consent of
the Disclosing Party, except to the extent that the Confidential Information (as determined by competent documentation):

 

9.1.1.     
was known or used by the Receiving Party prior to its date of disclosure to the Receiving Party; or

 

9.1.2.     
either before or after the date of the disclosure to the Receiving Party, is lawfully disclosed to the Receiving Party by
sources other than the Disclosing Party rightfully in possession of the Confidential Information; or

 

9.1.3.     
either before or after the date of the disclosure to the Receiving Party, becomes published or generally known to the public
(including information known to the public through the sale of products in the ordinary course of business) through no fault or
omission on the part of the Receiving Party or its sublicensees; or

 

9.1.4.     
is independently developed by or for the Receiving Party without reference to or reliance upon the Confidential Information.

 

9.2.           
Required Disclosures. Section 9.1 shall not preclude the Receiving Party from disclosing Confidential Information
to the extent such Confidential Information is required to be disclosed by the Receiving Party to comply with Applicable Laws,
to defend or prosecute litigation or to comply with governmental regulations, provided that the Receiving Party provides prior
written notice of such disclosure to the Disclosing Party and takes reasonable and lawful actions to avoid and/or minimize the
degree of such disclosure. If a public disclosure of Confidential Information is required by any Applicable Laws, including, without
limitation, in a filing with the United States Securities and Exchange Commission or submission to an exchange on which any securities
of a Party is listed, the disclosing Party shall provide copies of the disclosure (but shall be permitted to redact or omit portions
of any filing, submission or disclosure not relevant to this Agreement) reasonably in advance of such filing or other disclosure,
for the non-disclosing Party’s prior review and comment and to allow the other Party a reasonable time to object to any such
disclosure or to request confidential treatment thereof. The disclosing Party shall negotiate in good faith with the applicable
Regulatory Authority concerning the confidential treatment request. If the disclosure is substantially similar to prior disclosures
made by the Party and for which the obligations of this provision have been satisfied, the disclosing Party need not share such
disclosure ahead of it being made.

 

    -28-

     

    

 

  

 

9.3.           Permitted
Disclosures. MedImmune and Aevi each agree that that they shall provide Confidential Information received from the other Party
only to their respective directors, officers, employees, consultants, attorneys, vendors, suppliers, sublicensees, collaborators
and advisors who have a need to know for the Development, Manufacture, and Commercialization of Products in accordance with this
Agreement, for prosecution and maintenance of the MedImmune Patent Rights or to enforce or exercise rights under this Agreement,
including in connection with Regulatory Approval Applications and obtaining Regulatory Approvals, provided that such Third Parties
are bound by confidentiality obligations at least as strict as this Article 9. In addition, each Party may not disclose the terms
of this Agreement (to the extent such terms are confidential) to any Third Party except to actual or prospective lenders, investors,
acquirers, licensees/sublicensees or strategic partners or to a Party’s accountants, attorneys and other professional advisors;
provided that such disclosures shall be subject to continued confidentiality obligations at least as strict as this Article 9.

 

9.4.           Public Announcements and Use of Names. No public disclosure of the existence of, or the terms of, this Agreement
may be made by either Party, and no Party shall use the name, trademark, trade name or logo of the other Party in any publicity,
news release or public disclosure relating to this Agreement or its subject matter without the prior express written permission
of the other Party, except as may be required by Applicable Law or expressly permitted by the terms hereof. A press release agreed
upon by the Parties is attached to Exhibit A. If public disclosure of the terms of this Agreement beyond such press release
is required by any Applicable Law or the rules and regulations of any securities exchange on which a Party’s securities are
traded, the disclosing Party shall provide copies of the disclosure reasonably in advance of such filing or other disclosure, but
not later than five (5) Business Days prior to the filing, for the non-disclosing Party’s prior review and comment and to
allow the other Party a reasonable time to object to any such disclosure or to request confidential treatment thereof. If the disclosure
is substantially similar to prior disclosures made by the Party and for which the obligations of this provision have been satisfied,
the disclosing Party need not share such disclosure ahead of it being made.

 

Article
10 

TERM AND TERMINATION

 

10.1.       
Term. This Agreement shall commence on the Agreement Effective Date and remain in effect until terminated in accordance
with the terms of this Agreement, (the “Term”), provided, however, that if Aevi has not provided an Election
Notice to MedImmune by 5:00 PM Eastern Time on last day of the Deadline (or any relevant Extended Deadline) the Agreement will
automatically terminate. After expiration of the Royalty Term for a Product in a given country, no further royalties shall be payable
in respect of sales of such Product in such country, and the license granted to Aevi under Section 3.1 shall be a fully paid-up,
perpetual, irrevocable, royalty-free and sublicensable license with respect to such Product in such country.

 

    -29-

     

    

 

10.2.       
Termination by MedImmune.

 

10.2.1. 
Breach. MedImmune will have the right to terminate this Agreement in its entirety, subject to Section 10.2.2, upon
delivery of written notice to Aevi in the event of any material breach by Aevi of this Agreement, provided that such breach has
not been cured within sixty (60) days after written notice of such breach and MedImmune’s intention to terminate is given
by MedImmune to Aevi. Subject to Section 10.2.2, any such termination of this Agreement will become effective at the end of such
sixty (60) day cure period, unless Aevi has cured any such breach or default prior to the expiration of such cure period, or, if
such breach is not susceptible to cure within the sixty (60) day cure period, then, MedImmune’s right of termination will
be suspended only if and for so long as Aevi has provided to MedImmune a written plan that is reasonably calculated to effect a
cure within six (6) months thereafter and such plan is acceptable to MedImmune (such acceptance not to be unreasonably withheld,
conditioned, or delayed), and Aevi commits to and carries out such plan as provided to MedImmune.

 

10.2.2. 
Dispute. If Aevi reasonably and in good faith disagrees as to whether MedImmune has a basis for terminating this
Agreement pursuant to Section 10.2.1, Aevi may contest the allegation in accordance with Sections 12.2 and 12.17. It is understood
and acknowledged that, during the pendency of such a dispute, the remaining cure period shall be tolled and all of the terms and
conditions of this Agreement will remain in effect, and the Parties will continue to perform all of their respective obligations
under this Agreement. No termination by MedImmune pursuant to Section 10.2.1 will be effective unless and until (a) MedImmune’s
right to terminate this Agreement under Section 10.2.1 has been finally determined by litigation in accordance with Section 12.2
and (b) Aevi fails to cure the breach giving rise to the right to terminate during the cure period that remains following such
determination.

 

10.2.3. 
Abandonment. If Aevi, in its discretion, decides to abandon all of its Development and/or Commercialization efforts
with respect to the Products, Aevi shall promptly notify MedImmune in writing of its intent to do so. MedImmune will have the right
to terminate this Agreement immediately upon receipt of such notice.

 

10.3.       
Termination by Aevi.

 

10.3.1. 
Cell Line Viability. The Parties acknowledge that following the transfer of the Cell Line to Aevi’s contract
manufacturer (the “CMO”) pursuant to Section 4.3, Aevi will promptly instruct the CMO, using standard
cell manufacturing techniques, to thaw one randomly selected vial of Cell Line from the Cell Line stored at each of the GPF and
Fisher facilities (i.e. two total vials) and attempt to grow cells therefrom so as to confirm that the Cell Line remains alive
and able to produce a working cell bank therefrom. If, after such activities, the CMO notifies Aevi that it was not able to produce
living cells from such vials, Aevi shall notify MedImmune of such fact, and the Parties shall promptly discuss a remediation plan
including that MedImmune will provide technical support reasonably requested by Aevi. If the Parties are unable to agree on remediation
plan within sixty (60) days of the date of Aevi’s notice to MedImmune or if after completing the remediation plan, living
cells are not produced from the Cell Line, Aevi may terminate this Agreement on written notice to MedImmune.

 

    -30-

     

    

  

10.3.2. 
Breach. Aevi will have the right to terminate this Agreement in its entirety or on a Product-by-Product basis upon
delivery of written notice to MedImmune in the event of any material breach of this Agreement by MedImmune including any failure
to provide the Antibody Material and the Cell Line in accordance with this Agreement, and, provided that such breach has not been
cured within sixty (60) days after written notice of such breach and Aevi’s intention to terminate is given by Aevi to MedImmune.
Any such termination will become effective at the end of such sixty (60) day cure period, unless MedImmune has cured any such breach
or default prior to the expiration of such cure period, or, if such breach is not susceptible to cure within the sixty (60) day
cure period, then, Aevi’s right of termination will be suspended only if and for so long as MedImmune has provided to Aevi
a written plan that is reasonably calculated to effect a cure within six (6) months thereafter and such plan is acceptable to Aevi
(such acceptance not to be unreasonably withheld, conditioned, or delayed), and MedImmune commits to and carries out such plan
as provided to Aevi.

 

10.3.3. 
Convenience. Upon (a) written notice in the case where Aevi has not provided an Exercise Notice to MedImmune, (b)
thirty (30) days prior written notice in the case where Regulatory Approval for Commercialization has not been obtained for any
Product in the Field in a jurisdiction in the Territory or (c) ninety (90) days prior written notice in the case where Regulatory
Approval for Commercialization in the Field in a jurisdiction in the Territory has been obtained for a Product, such termination
to be effective at the end of such notice period, Aevi may terminate this Agreement as to a Product or jurisdiction or this Agreement
in its entirety for any reason or no reason, including if Aevi decides to cease all of its Development and/or Commercialization
efforts with respect to a Product in a jurisdiction.

 

10.4.       
Effects of Termination. 

 

10.4.1. 
Cell Line Termination. If Aevi terminates this Agreement pursuant to Section 10.3.1, then promptly after the request
of MedImmune, Aevi or the CMO shall deliver to MedImmune or its designee all remaining quantities of Antibody Material, Clinical
Material and Cell Line at no charge to MedImmune other than packing and transportation. Such delivery shall be FCA (Incoterms 2010)
Aevi’s place of shipment. MedImmune shall pay Aevi’s invoice for packing and transportation costs within thirty (30)
days after receipt of all such materials and Aevi’s invoice. If such request is not made within thirty (30) days after the
effective date of termination of this Agreement, Aevi may destroy all such materials, and MedImmune shall reimburse Aevi for the
costs of such destruction within thirty (30) days after receipt of invoice therefor.

 

10.4.2. 
Wind-Down or Transfer of Clinical Studies. Unless expressly prohibited by any Regulatory Authority, at MedImmune’s
written request, Aevi shall, and shall cause its Affiliates and its and their sublicensees to, (a) transfer control to MedImmune
of any or all clinical studies involving the Molecule being conducted by or on behalf of Aevi, an Affiliate or a sublicensee as
of the effective date of termination and (b) continue to conduct such clinical studies, at Aevi’s cost, for up to nine (9)
months to enable such transfer to be completed without interruption of any such clinical study; provided that (x) MedImmune
shall not have any obligation to continue any clinical study unless required by Applicable Law and (y) with respect to each
clinical study for which such transfer is expressly prohibited by the applicable Regulatory Authority, if any, Aevi shall continue
to conduct such clinical study to completion, at Licensee’s cost and expense.

 

    -31-

     

    

  

10.4.3. 
Termination by MedImmune for Aevi’s Breach. Without limiting any other legal or equitable remedies that MedImmune
may have, if MedImmune terminates this Agreement in accordance with Section 10.2.1, then:

 

(a)           MedImmune
may elect to terminate all related licenses granted under this Agreement subject to Section 3.2.3;

 

(b)           Aevi shall assign and promptly transfer to MedImmune or its Affiliate, as requested by MedImmune, and MedImmune shall assume
and thereafter be fully responsible and liable for and indemnify and hold harmless Aevi with respect to any reliance, use, practice
or exploitation of all Regulatory Approval Applications and Regulatory Approvals for the Molecule and Product(s);

 

(c)           Aevi
shall grant MedImmune and its Affiliates a perpetual, royalty-bearing, and exclusive license in the Field in the Territory under
all Aevi Intellectual Property to Develop, have Developed, Manufacture, have Manufactured, Commercialize and have Commercialized
the Molecule in the Field in the Territory, subject to MedImmune defending, indemnifying and holding harmless Aevi and its Affiliates
from any and all claims that arise from the Development, Manufacture and/or Commercialization of the Molecule and Products in
the Field in the Territory by any of MedImmune or its Affiliates or licensees and sublicense and further subject to payment of
royalty to Aevi as set forth in Sections 10.4.5(a) and 10.4.5(c). Aevi shall also transfer copies of the Aevi Know-How to MedImmune.

 

(d)           MedImmune may elect to have any agreements to which Aevi is a party providing solely for Development, Commercialization
or Manufacturing services for the Molecule or Product(s) in the Territory such as contract research organization contracts and
contract manufacturing organization contracts, assigned to MedImmune, to the extent permitted by such agreements and not cancelled,
and thereafter MedImmune shall indemnify and hold harmless Aevi from any liabilities arising under such agreements from and after
the applicable date of assignment and assumption.

 

10.4.4. 
Termination by Aevi for MedImmune’s Breach. Without limiting any other legal or equitable remedies that Aevi
may have, if Aevi terminates this Agreement in accordance with Section 10.3.1, then in addition to any other remedies available
to it at law and equity Aevi may, upon its election to do so, terminate any agreements to which Aevi is a party providing for Development,
Commercialization or Manufacturing services for the Molecule or Product(s) such as contract research organization contracts and
contract manufacturing organization contracts, and MedImmune shall indemnify and hold harmless Aevi in accordance with Section
11.6.2 against any liabilities or obligations arising under such agreements as a result of such terminations in accordance with
the terms of this Agreement.

 

    -32-

     

    

  

10.4.5. 
Termination for Abandonment or Convenience. If the Agreement is terminated pursuant to Sections 10.2.3 or 10.3.3,
then:

 

(a)            the
effects of termination set forth in Section 10.4.1 and 10.4.2 shall apply; and

 

(b)           MedImmune
shall pay Aevi royalties on Products that in any way rely on, practice or use any of the Aevi Intellectual Property or the Regulatory
Approval Applications or Regulatory Approvals transferred to MedImmune or its Affiliates as a percentage of Annual Net Sales generated
in each country of sale of the Products in the Territory as follows:

 

	Stage of Development of the Product as of the 

Effective Date of Termination	Royalty Rate
	(***)	(***%***)
	(***)	(***%***)
	(***)	(***%***)

 

(c)            In
connection with the royalty set forth in Section 10.4.5(a), MedImmune shall comply with the obligations under Sections 7.4, 7.5
and 7.6, and Aevi shall have the rights under such Sections, except that all references to Aevi in such Sections (as well as the
definitions of Net Sales) shall refer to MedImmune and all references to MedImmune in such Sections shall refer to Aevi. For clarity,
the royalty set forth in Section 10.4.5(a) shall be Aevi’s sole and exclusive compensation for granting MedImmune a license
to Aevi Intellectual Property.

 

10.5.       
Rights in Bankruptcy. All rights and licenses granted under or pursuant to this Agreement, including without limitation
Article 3, are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code or analogous provisions
of Applicable Law outside the United States, licenses of right to “intellectual property” as defined under Section 101
of the Bankruptcy Code or analogous provisions of Applicable Law outside the United States (hereinafter “IP”).
Upon a Party which is a licensor or rights granted under this Agreement entering into any voluntary or involuntary insolvency proceeding
during the Term of this Agreement, and notwithstanding any attempted termination of this Agreement by any trustee, administrator
or executor of such Party or an applicable bankruptcy court, the Parties agree that: the other Party, as licensee of such rights
under this Agreement, shall (i) retain and may fully exercise all of its rights and elections under the Bankruptcy Code or any
other provisions of Applicable Law outside the United States that provide similar protection for IP and (ii) retain in perpetuity
all rights and licenses herein grant provided such Party continues to pay any royalties otherwise due hereunder (subject to any
right of set-off hereunder) and the Party which has entered such insolvency proceeding shall have, to the extent required by applicable
bankruptcy laws in order to maintain the other Party's license rights hereunder, no further obligations under this Agreement other
than to not interfere with such other Party's license rights hereunder. Each Party hereby grants to the other Party and its Affiliates
a right to obtain possession of and to benefit from a complete duplicate of (or complete access to, as appropriate) any such IP
and all embodiments of intellectual property, which, if not already in the other Party’s possession, shall be promptly delivered
to it upon the other Party’s written request therefor. The term “embodiments of intellectual property” includes
all tangible, electronic or other embodiments of rights and licenses hereunder, including the Molecule, Product(s), all Regulatory
Approval Applications and Regulatory Approvals, and all Information related to the Molecule and Product(s), MedImmune Patent Rights
and MedImmune Know-How, or Aevi Patent Rights and Aevi Know-How, as applicable. Neither Party shall interfere with the exercise
by the other Party or its Affiliates of rights and licenses to IP and embodiments of intellectual property licensed hereunder in
accordance with this Agreement, and each Party agrees to reasonably assist the other Party and its Affiliates to obtain the IP
and embodiments of intellectual property in the possession or control of Third Parties as reasonably necessary or desirable for
the other Party or its Affiliates to exercise such rights and licenses in accordance with this Agreement. The Parties agree that
the terms of this Agreement are fair and reasonable, are not overly burdensome and have been negotiated in an arms-length transaction
between unrelated parties with each Party represented by legal counsel. If any provision herein is deemed onerous or otherwise
unenforceable by any applicable bankruptcy court, the Parties shall use good faith efforts to amend the Agreement (e.g., removing
such onerous provision) so as to avoid any consequences thereof under applicable bankruptcy laws

 

    -33-

     

    

 

10.6.       
Return of Confidential Information. Except to the extent otherwise required by Applicable Law, upon termination of
this Agreement, each Party shall promptly return to the other Party, delete or destroy all relevant records and materials in such
Party’s possession or control containing Confidential Information of the other Party; provided that such Party may keep copies
of such materials in order to satisfy regulatory requirements or obligations under Applicable Law or for archival purposes only.
Each Party’s obligations under Article 9 terminate on the date that is five (5) years after the effective date of termination
of this Agreement.

 

10.7.       
Survival. The provisions of Article 9 (Confidentiality), Article 11 (Representations and Warranties; Indemnification)
and Article 12 (Miscellaneous Provisions) and Sections 3.2.3 (Effect of Termination on Sublicenses), 10.4 (Effect of Termination),
10.6 (Return of Confidential Information) and 10.7 (Survival), any accrued obligation by either Party to make any payment prior
to the effective date of termination, and any provision necessary to interpret or give effect to such Sections shall survive any
termination of this Agreement in accordance with their respective terms. Except as set forth in this 10.7, upon termination or
expiration of this Agreement all other rights and obligations cease. Any termination of this Agreement shall be without prejudice
to the rights of either Party against the other accrued or accruing under this Agreement before termination.

 

Article
11 

REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION

 

11.1.       
Mutual Representations and Warranties. Each Party represents and warrants to the other Party, as of the Agreement
Effective Date and covenants that:

 

11.1.1. 
Existence and Authority. It is a corporation (in the case of Aevi) or a limited liability company (in the case of
MedImmune) duly organized, validly existing and in good standing under the laws of its jurisdiction of organization, and has full
power and authority to enter into this Agreement and to carry out the provisions hereof.

 

    -34-

     

    

 

11.1.2. 
Authorized Execution; Binding Obligation.

 

(a)            The execution, delivery, and performance of this Agreement and the consummation of the transactions contemplated by this
Agreement have been duly authorized and approved by all necessary corporate or company action on its part; and

 

(b)           This Agreement has been duly executed and delivered by it and constitutes a legal, valid, and binding obligation enforceable
against it in accordance with its terms.

 

11.1.3. 
No Conflicts. The execution, delivery and performance of this Agreement by it does not conflict with any agreement,
instrument or understanding, oral or written, to which it is a party and by which it or its assets may be bound.

 

11.1.4. 
All Consents and Approvals Obtained. Except for Competition Law Approvals, (a) all necessary consents, approvals
and authorizations of, and (b) all notices to, and filings by such Party with, all governmental authorities and other Persons required
to be obtained or provided by such Party in connection with the execution, delivery and performance of this Agreement have been
obtained.

 

11.1.5. 
Compliance with Law. It shall at all times comply with Applicable Laws in all material respects with respect to its
activities under this Agreement. Neither it nor any of its Affiliates nor any director, officer, agent, employee, consultant of,
or other person associated with, or acting on behalf of, it or its Affiliates has (a) made, authorized, offered or promised to
make any payment or transfer of anything of value, directly, indirectly or through a third party, to any foreign government official,
employee or other representative (including employees of a government owned or controlled entity or public international organization
and including any political party or candidate for public office), in violation of any Anti-Bribery Laws, or any law of similar
effect in any jurisdiction to which such Person is subject or (b) otherwise taken any action in violation of any Anti-Bribery Laws,
or any law of similar effect in any jurisdiction to which such Person is subject. For the purposes of this Section 11.1.5, the
acts specified include (x) the making or payment of any illegal contributions, commissions, fees, gifts, entertainment, travel
or other unlawful expenses relating to political activity, (y) the direct or indirect payment, gift, offer, promise or authorization
to make a payment, gift, offer or promise of, anything of material value to any foreign government representative and (z) the making
of any bribe, illegal payoff, influence payment, kickback or other unlawful payment. “Anti-Bribery Laws”
means the United States Foreign Corrupt Practices Act of 1977 or any other anti-bribery laws, statutes, rules or regulations of
any country that may be applicable to a Party, including the United Kingdom Bribery Act 2010 and any anti-bribery and related prohibitions
implemented under the Organization for Economic Cooperation and Development Convention on Combating Bribery of Foreign Public Officials
in International Business Transactions.

 

11.2.       
MedImmune Representations and Warranties. MedImmune represents and warrants to Aevi that as of the Agreement Effective
Date of this Agreement:

 

    -35-

     

    

 

11.2.1. 
MedImmune Intellectual Property. MedImmune Controls the MedImmune Intellectual Property existing as of the Agreement
Effective Date and is entitled to grant the licenses specified herein. The MedImmune Know-How that will be listed in Schedule
2.1.46 will contain, to the knowledge of MedImmune, substantially all the Know-How Controlled by MedImmune as of the Agreement
Effective Date with respect to the Molecule excluding MedImmune Excluded IP. MedImmune will deliver to Aevi all the MedImmune Know-How
listed in Schedule 2.1.46. The MedImmune Patent Rights listed on Schedule 2.1.47 constitute all of the Patent Rights
Controlled by MedImmune as of the Agreement Effective Date that, but for the license granted by Section 3.1, would be infringed
by the Development, Manufacture and/or Commercialization of the Molecule or a Product excluding the Patent Rights within the MedImmune
Excluded IP. MedImmune has not previously assigned, transferred, conveyed or otherwise encumbered its right, title and interest
in the MedImmune Intellectual Property in a manner that conflicts with any rights granted to Aevi hereunder, and MedImmune is under
no obligation to make any such transfers, conveyances or encumbrances.

 

11.2.2. 
Infringement. To the knowledge of MedImmune, there is no actual or threatened infringement or misappropriation of
the MedImmune Intellectual Property in the Field in the Territory by any Third Party or any other infringement, misappropriation
or threatened infringement or misappropriation that would adversely affect Aevi’s rights under this Agreement.

 

11.2.3. 
MedImmune Patent Rights. The MedImmune Patent Rights existing as of the Agreement Effective Date are subsisting and,
to the knowledge of MedImmune, are not invalid or unenforceable, in whole or in part. There are no written claims asserted or,
to MedImmune’s knowledge, threatened against MedImmune or judgments or settlements against or amounts with respect thereto
owed by MedImmune or any of its Affiliates relating to the MedImmune Patent Rights or the Molecule. No patent or patent application
within the MedImmune Patent Rights is the subject of any pending or, to the knowledge of MedImmune, threatened interference, opposition,
cancellation, protest, inventorship dispute or other challenge or adversarial proceeding. The MedImmune Patent Rights are free
of any and all liens and encumbrances. No claim or litigation has been brought or, to MedImmune’s knowledge, threatened by
any Third Party alleging that (a) the MedImmune Patent Rights are invalid, unpatentable or unenforceable, (b) the MedImmune Intellectual
Property or the licensing or exploiting of the MedImmune Intellectual Property violates, infringes, misappropriates or otherwise
conflicts or interferes with any intellectual property or proprietary right of any Third Party or (c) any Third Party has any right,
title, or interest in, to, and under any MedImmune Intellectual Property.

 

11.2.4. 
Claims; Judgments. There are no claims, judgments or settlements against or owed by MedImmune or pending or, to the
knowledge of MedImmune, threatened claims or litigation relating to the MedImmune Intellectual Property.

 

11.2.5. 
Disclosure. To the knowledge of MedImmune, MedImmune has disclosed to Aevi all material information and data (including
without limitation all communications with or from the FDA or any other Regulatory Authority) relating to the results of all preclinical
studies and clinical trials involving the Molecule. MedImmune has provided to Aevi all reports and data collections containing
information about adverse safety issues (including adverse drug experiences) related to the Molecule of which MedImmune has knowledge.
MedImmune represents that (a) to its knowledge, it has not failed to furnish Aevi with any information requested by Aevi or (b)
intentionally concealed from Aevi any information in MedImmune's possession which would be reasonably likely to be material to
Aevi's decision to enter into this Agreement and undertake the commitments and obligations set forth herein.

 

    -36-

     

    

 

11.2.6. 
Debarment and Compliance. Neither MedImmune nor any of its Affiliates nor any of their respective directors, officers,
employees, or consultants, and, to its knowledge based upon reasonable inquiry, any Third Party (and its directors, officers, employees
and consultants), in each case who were responsible for the Development of the Product prior to the Agreement Effective Date: (a)
were are debarred under Section 306(a) or 306(b) of the FD&C Act; (b) have been charged with, or convicted of, any felony or
misdemeanor under Applicable Laws related to any of the following: (i) the development or approval of any drug product or the regulation
of any drug product under the FD&C Act; or (ii) a conspiracy to commit, aid or abet the development or approval of any drug
product or regulation of any drug product; or (b) is excluded, suspended or debarred from participation, or otherwise ineligible
to participate, in any United States federal or state health care programs (including convicted of a criminal offense that falls
within the scope of 42 U.S.C. §1320a-7 but not yet excluded, debarred, suspended, or otherwise declared ineligible), or excluded,
suspended or debarred from participation, or otherwise ineligible to participate, in any United States federal procurement or non-procurement
programs

 

11.2.7. 
Securities Law Compliance. MedImmune has been advised that the Shares, when they are initially issued pursuant to
this Agreement, will not be registered under the Securities Act, or any state securities laws and, therefore, cannot be resold
unless they are registered under the Securities Act and applicable state securities laws or unless an exemption from such registration
requirements is available. The Shares to be acquired by MedImmune hereunder will be acquired for its own account for investment,
not as a nominee or agent, and not with a view to, or for resale in connection with, the distribution thereof, and, as of the Agreement
Effective Date and License Effective Date, MedImmune has no present intention of selling, granting any participation in, or otherwise
distributing the same. MedImmune has such knowledge and experience in financial and business matters that MedImmune is capable
of evaluating the merits and risks of such investment, is able to incur a complete loss of such investment without impairing MedImmune’s
financial condition and is able to bear the economic risk of such investment for an indefinite period of time. MedImmune is an
 “Accredited Investor” as such term is defined in Rule 501(a) under the Securities Act.

 

11.2.8. 
Access to Information. MedImmune acknowledges and agrees that (a) it has been furnished with all materials it
considers relevant to making an investment decision with respect to the issuance of Shares and has had the opportunity to review
(and has carefully reviewed) Aevi’s filings and submissions with the SEC, including, without limitation, all information
filed or furnished pursuant to the Exchange Act (collectively, the “Public Filings”), (b) MedImmune
has had an opportunity to ask questions of Aevi concerning the company, its business, operations, financial performance, financial
condition and prospects, and to obtain from Aevi any information that it considers necessary in making an informed investment decision
and to verify the accuracy of the information set forth in the Public Filings, (c) MedImmune has had the opportunity to consult
with its accounting, tax, financial and legal advisors to be able to evaluate the risks involved with respect to the issuance of
Shares and to make an informed investment decision with respect to such issuance, (d) MedImmune is not relying, and has not
relied, upon any statement, advice (whether accounting, tax, financial, legal or other), representation or warranty made by Aevi
or any of its affiliates or representatives or any other entity or Person, other than statements in the Public Filings or statements,
representations and warranties, as applicable, in this Agreement, (e) to MedImmune’s knowledge, no statement or written material
contrary to the Public Filings has been made or given to MedImmune by or on behalf of Aevi, and (f) MedImmune is able to fend for
itself with respect to the issuance of Shares, has such knowledge and experience in financial and business matters as to be capable
of evaluating the merits and risks of the prospective investment in Aevi and has the ability to bear the economic risks of its
investment and can afford the complete loss of such investment.

 

    -37-

     

    

 

11.2.9. 
Tax Advisors. MedImmune has reviewed with its own tax advisors the U.S. federal, state and local and
non-U.S. tax consequences of this investment and the transactions contemplated by the issuance of Shares. With respect to such
matters, MedImmune relies solely on any such advisors and not on any statements or representations of Aevi or any of its agents,
written or oral. MedImmune understands that it (and not Aevi) shall be responsible for its own tax liability that may arise as
a result of this investment and the transactions contemplated by the issuance of Shares.

 

11.3.       
Aevi Representations and Warranties. Aevi represents and warrants to MedImmune that as of the Agreement Effective
Date of this Agreement and as of the date the Shares are issued pursuant to Section 7.1.2:

 

11.3.1. 
Issuance of the Shares. The issuance of the Shares has been duly authorized by all necessary Board and shareholder
action and the Shares, when issued in accordance with the terms of this Agreement, will be duly and validly issued, fully paid,
and non-assessable and free and clear of all liens, other than restrictions on transfer imposed by applicable securities laws.

 

11.3.2. 
SEC Reports; Disclosure Materials. Aevi has filed all reports, schedules, forms, statements, and other documents
required to be filed by it under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the 24 months prior
to the Agreement Effective Date on a timely basis or has received a valid extension of such time of filing and has made any such
filings prior to the expiration of any such extension. As of their respective filing dates, the Public Filings complied in all
material respects with the requirements of the Securities Act and the Exchange Act and the rules and regulations of the SEC promulgated
thereunder. Since the date of the last audited financial statements included within the Public Filings, except as specifically
disclosed in the Public Filings, there has been no event, occurrence or development that has had or that could reasonably be expected
to result in a material adverse effect on Aevi’s business, assets (including intangible assets), liabilities, financial condition,
results of operations or prospects.

 

11.3.3. 
Private Placement. Assuming the accuracy of MedImmune’s representations and warranties set forth in Section
11.2 of this Agreement, no registration under the Securities Act is required for the offer and sale of the Shares by Aevi to MedImmune
under this Agreement.

 

11.3.4. 
Shell Company Status. Aevi is not, and has never been, an issuer identified in Rule 144(i)(1).

 

    -38-

     

    

 

11.3.5. 
Investment Company. Aevi is not, and is not an Affiliate of, an “investment company” within the meaning
of the Investment Company Act of 1940, as amended.

 

11.3.6. 
Listing and Maintenance Requirements. Aevi’s Common Stock is registered pursuant to Section 12(g) of the Exchange
Act, and Aevi has taken no action designed to terminate the registration of the Common Stock under the Exchange Act nor has Aevi
received any written notification that the SEC is contemplating terminating such registration. Other than as disclosed in the Public
Filings, Aevi has not, in the past twelve (12) months preceding the Agreement Effective Date, received written notice from the
Nasdaq Global Market or any other trading market on which the Common Stock is listed or quoted to the effect that Aevi is not in
compliance with the listing or maintenance requirements of such trading market.

 

11.3.7. 
Disclosure. Aevi understands and confirms that MedImmune will rely on the representations in this Agreement in making
its investment decision with respect to the Shares. The disclosures contained in Aevi’s Public Filings are true and correct
in all material respects and do not contain any untrue statement of material fact or omit to state any material fact necessary
in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.

 

11.4.       
Warranty Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION
OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY WITH RESPECT TO ANY TECHNOLOGY OR OTHER SUBJECT
MATTER OF THIS AGREEMENT AND HEREBY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT
WITH RESPECT TO ANY AND ALL OF THE FOREGOING. EACH PARTY HEREBY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE DEVELOPMENT,
MANUFACTURE OR COMMERCIALIZATION OF ANY PRODUCT UNDER THIS AGREEMENT WILL BE SUCCESSFUL. AEVI AGREES THAT (A) MEDIMMUNE WILL HAVE
NO LIABILITY TO AEVI FOR ANY ACT OR OMISSION IN THE PREPARATION, FILING, PROSECUTION, MAINTENANCE, ENFORCEMENT, DEFENSE, OR OTHER
HANDLING OF THE MEDIMMUNE PATENT RIGHTS PRIOR TO THE EFFECTIVE DATE; AND (B) ASSUMING THE ACCURACY OF MEDIMMUNE’S REPRESENTATIONS
AND WARRANTIES SET FORTH IN SECTION 11.2, AEVI IS SOLELY RESPONSIBLE FOR DETERMINING WHETHER THE MEDIMMUNE INTELLECTUAL PROPERTY
HAS APPLICABILITY OR UTLITY IN AEVI’S CONTEMPLATED EXPLOITATION OF THE MOLECULE OR THE PRODUCTS AND ASSUMES ALL RISK AND
LIABILITY IN CONNECTION WITH SUCH DETERMINATION.

 

11.5.       
No Consequential Damages. NEITHER PARTY HERETO WILL BE LIABLE FOR SPECIAL,
INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING WITHOUT LIMITATION
LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES. NOTHING IN THIS
SECTION 11.5 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY OR TO LIMIT A PARTY’S
LIABILITY FOR BREACHES OF ITS OBLIGATION REGARDING CONFIDENTIALITY UNDER Article 9.

 

    -39-

     

    

 

  

11.6.       
Indemnification and Insurance. 

 

11.6.1. 
Indemnification by Aevi. Aevi shall indemnify, hold harmless, and defend MedImmune, its Affiliates, and their respective
directors, officers, employees and agents (“MedImmune Indemnitees”) from and against any and all damages,
settlements, costs (including without limitation reasonable legal expenses, costs of litigation and reasonable attorneys’
fees) or judgments of any kind (collectively, “Losses”) arising out of any Third Party claim, suit or
proceeding, whether for money or equitable relief (each, a “Third Party Claim”), to the extent arising
out of or resulting from, directly or indirectly: (a) any material breach of, or inaccuracy in, any representation or warranty
made by Aevi in this Agreement, or any breach or violation of any covenant or agreement of Aevi or any of its Affiliates or sublicensees
in or pursuant to this Agreement, (b) the negligence or willful misconduct by or of Aevi or its Affiliates, and their respective
directors, officers, employees and agents, (c) the Development, Manufacturing and/or Commercialization of the Product by Aevi or
its Affiliates or sublicensees (including product liability) during the Term, and (d) any untrue or alleged untrue statement of
a material fact contained in the Registration Statement or any successor registration statement, prospectus or preliminary prospectus
or any amendment thereof or supplement thereto, or any omission or alleged omission of a material fact required to be stated therein
or necessary to make the statements therein not misleading; provided, that Aevi will have no obligation to provide any indemnification
hereunder to the extent that any such Losses (or actions or proceedings in respect thereof) arise out of or are based upon an untrue
statement or alleged untrue statement or omission or alleged omission made in such registration statement, prospectus, or any preliminary
prospectus or any amendment thereof or supplement thereto, in reliance upon and in substantial conformity with information furnished
in writing to Aevi by MedImmune or any of its Affiliates for use therein.

 

11.6.2. 
Indemnification by MedImmune. MedImmune shall indemnify, hold harmless, and defend Aevi, its Affiliates and their
respective directors, managers, officers, employees and agents (“Aevi Indemnitees”) from and against
any and all Losses arising out of any Third Party Claims to the extent arising out of or resulting from, directly or indirectly,
(a) any material breach of, or inaccuracy in, any representation or warranty made by MedImmune in this Agreement, or any breach
or violation of any covenant or agreement of MedImmune in or pursuant to this Agreement, (b) the negligence or willful misconduct
by or of MedImmune, its Affiliates, and their respective directors, officers, employees and agents, (c) the Development, Manufacture,
and/or Commercialization of any Product by or on behalf of MedImmune or its Affiliates or licensees (other than Aevi and its Affiliates),
(d) the use, reliance, practice or exploitation of any Aevi Intellectual Property by MedImmune, its Affiliates and/or sublicensees
of MedImmune, and (e) any untrue or alleged untrue statement of a material fact contained in the Registration Statement or any
successor registration statement, prospectus or preliminary prospectus or any amendment thereof or supplement thereto, or any omission
or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading,
but only to the extent that such untrue statement or alleged untrue statement or omission or alleged omission is contained in any
information furnished in writing to Aevi by MedImmune or any of its Affiliates for use therein.

 

    -40-

     

    

 

11.6.3. 
Indemnification Procedure. In the event of any Third Party Claim against any Aevi Indemnitee or MedImmune Indemnitee
(individually, an “Indemnitee”), the indemnified Party shall promptly notify the other Party in writing
of the claim and the indemnifying Party shall manage and control, at its sole expense, the investigation and defense of the Third
Party Claim and its settlement; provided that the failure to so notify promptly shall not relieve the indemnifying Party of its
obligations under this Section 11.6 except to the extent of the actual prejudice suffered by such Party as a result of such failure.
The Indemnitee shall cooperate with the indemnifying Party and may, at its option and expense, be represented in any such action
or proceeding. The indemnifying Party shall not be liable for any settlements, litigation costs or expenses incurred by any Indemnitee
without the indemnifying Party’s written authorization. Notwithstanding the foregoing, if the indemnifying Party believes
that any of the exceptions to its obligation of indemnification of the Indemnitees set forth in Section 11.6 or Section 11.6.2
may apply, the indemnifying Party shall promptly notify the Indemnitees, which shall then have the right to be represented in any
such action or proceeding by separate counsel at their expense; provided that the indemnifying Party shall be responsible for payment
of such expenses if the Indemnitees are ultimately determined to be entitled to indemnification from the indemnifying Party. The
indemnifying Party shall not effect any settlement of any such claims without the consent of the Indemnitee, which consent shall
not be unreasonably withheld or delayed.

 

Article
12 

MISCELLANEOUS PROVISIONS

 

12.1.       
Governing Law. This Agreement shall be construed and the respective rights of the Parties determined according to
the substantive laws of the State of Delaware notwithstanding the provisions governing conflict of laws under the law of any jurisdiction
to the contrary.

 

12.2.       
Jurisdiction; Venue; Service of Process.

 

12.2.1. 
Jurisdiction. Each Party by its execution hereof, (a) hereby irrevocably submits to the exclusive jurisdiction of
the state courts of the State of Delaware or the United States District Court with jurisdiction over Delaware for the purpose of
any claim, controversy, action, cause of action, suit or litigation (“Action”) between the Parties arising
in whole or in part under or in connection with this Agreement, (b) hereby waives to the extent not prohibited by Applicable Law,
and agrees not to assert, by way of motion, as a defense or otherwise, in any such Action, any claim that it is not subject personally
to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that any such
Action brought in one of the above-named courts should be dismissed on grounds of forum non conveniens, should be transferred or
removed to any court other than one of the above-named courts, or should be stayed by reason of the pendency of some other proceeding
in any other court other than one of the above-named courts, or that this Agreement or the subject matter hereof may not be enforced
in or by such court and (c) hereby agrees not to commence any such Action other than before one of the above-named courts. Notwithstanding
the previous sentence, a Party may commence any Action in a court other than the above-named courts solely for the purpose of enforcing
an order or judgment issued by one of the above-named courts or to obtain emergency or temporary injunctive relief.

 

    -41-

     

    

 

12.2.2. 
Venue. Each Party agrees that for any Action between the Parties arising in whole or in part under or in connection
with this Agreement, such Party may bring Actions only in the State of Delaware. Each Party further waives any claim and shall
not assert that venue should properly lie in any other location within the selected jurisdiction.

 

12.2.3. 
Service of Process. Each Party hereby (a) consents to service of process in any Action between the Parties arising
in whole or in part under or in connection with this Agreement in any manner permitted by Delaware law, (b) agrees that service
of process made in accordance with clause (a) or made by registered or certified mail, return receipt requested, at its address
specified pursuant to Section 12.5, shall constitute good and valid service of process in any such Action and (c) waives and agrees
not to assert (by way of motion, as a defense, or otherwise) in any such Action any claim that service of process made in accordance
with clause (a) or (b) does not constitute good and valid service of process.

 

12.3.       
Assignment. This Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder
be assigned or transferred, by either Party without the prior, written consent of the other Party. Notwithstanding the foregoing,
(a) MedImmune may monetize the value of its royalty stream, Milestone Payments and other payments under this Agreement by assigning
to a Third Party the right to receive royalties, Milestone Payments and other payments and the right to receive royalty reports
from Aevi; provided that MedImmune gives sixty (60) days’ prior written notice to Aevi, and (b) either Party may, without
the other Party’s consent, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate
or pursuant to a Change of Control. The assigning Party shall remain responsible for the performance by its assignee of this Agreement
or any obligations hereunder so assigned to such assignee. Without limiting the foregoing, MedImmune shall not assign or transfer
any of its rights in or to the MedImmune Intellectual Property to any Third Party other than a Third Party to which it is assigning
this Agreement in its entirety.

 

12.4.       
Amendments. This Agreement and the Schedules and Exhibits referred to in this Agreement constitute the entire agreement
between the Parties with respect to the subject matter hereof, and supersede all previous arrangements with respect to the subject
matter hereof, whether written or oral, including the Confidentiality Agreement. Any amendment or modification to this Agreement
shall be made in writing signed by both Parties.

 

    -42-

     

    

 

12.5.       
Notices. Any consent, notice or report required or permitted to be given or made under this Agreement by one of the
Parties to the other shall be in writing and (a) delivered by hand, or (b) sent by internationally recognized delivery service
and shall be deemed to have been properly served to the addressee upon receipt of such written communication or refusal to accept
delivery, to the following addresses:

 

	If to MedImmune:	MedImmune Limited
	 	1 Francis Crick Avenue
	 	Cambridge Biomedical Campus 
Cambridge
	 	CB2 0AA
	 	England
	 	Attention: Vice President, Scientific Partnering and Alliances 

	 	 
	with a copy (which shall not constitute notice) to:	AstraZeneca UK Limited
	 	Corporate Legal
	 	Middlewood Court, Silk Road
	 	Macclesfield, Cheshire
	 	SK10 2NA
	 	England
	 	Email: legalnotices@astrazeneca.com
	 	Attention: Assistant General Counsel
	 	 
	If to Aevi:	Aevi Genomic Medicine, Inc.
	 	435 Devon Park Drive, Suite 715
	 	Wayne, Pennsylvania 19087 
USA
	 	Attention: Chief Executive Officer
	 	 
	with a copy (which shall not constitute notice) to:	Pepper Hamilton LLP
	 	400 Berwyn Park
	 	899 Cassatt Road
	 	Berwyn, Pennsylvania 19312 
USA
	 	Attention: Brian M. Katz, Esq. 

 

  Either Party may change its address to which
notices shall be sent by giving notice to the other Party in the manner herein provided.

 

12.6.       
Force Majeure. The failure of either Party to timely perform any obligation under this Agreement by reason of epidemic,
earthquake, riot, civil commotion, fire, act of God, war, terrorist act, strike, flood, or governmental act or restriction, or
other cause that is beyond the reasonable control of and without the fault or negligence of the respective Party (such reasons
or causes being “Force Majeure”), shall not be deemed to be a material breach of this Agreement, but
shall be excused to the extent and for the duration of such Force Majeure, and the affected Party shall provide the other Party
with full particulars thereof as soon as it becomes aware of the same (including its best estimate of the likely extent and duration
of the interference with its activities) and shall use its Commercially Reasonable Efforts to avoid or remove such Force Majeure.
If the performance of any such obligation under this Agreement is delayed owing to Force Majeure for any continuous period of more
than one hundred eighty (180) days, the Parties shall consult with respect to an equitable solution.

 

    -43-

     

    

 

12.7.       
Compliance with Export Regulations. Neither Party shall export any technology licensed to it by the other Party under
this Agreement except in compliance with US export laws and regulations.

 

12.8.       
Independent Contractors. It is understood and agreed that the relationship between the Parties is that of independent
contractors and that nothing in this Agreement shall be construed as authorization for either MedImmune or Aevi to act as agent
for the other. Nothing in this Agreement shall be deemed to create an employment, agency, joint venture or partnership relationship
between the Parties or any of their agents or employees for any purpose, including tax purposes, or to create any other legal arrangement
that would impose liability upon one Party for the act or failure to act of the other Party. Neither Party shall have any express
or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other
Party, or to bind the other Party in any respect whatsoever.

 

12.9.       
Further Assurances. Each Party shall execute, acknowledge and/or deliver such further instruments, and to do all
other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

 

12.10.   
  No Strict Construction. This Agreement has been prepared jointly and shall not be strictly construed
against either Party.

 

12.11.   
  Performance by Affiliates. MedImmune recognizes that Aevi may perform some or all of its obligations
under this Agreement through Affiliates; provided, however, that Aevi will remain responsible for the performance by its Affiliates
as if such obligations were performed by Aevi.

 

12.12.   
  Construction. Except where the context otherwise requires, wherever used, the singular will include the plural, the
plural the singular, and the use of any gender will be applicable to all genders. The captions of this Agreement are for convenience
of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision
contained in this Agreement. The term “including” as used herein means including, without limiting the generality of
any description that precedes such term, and will be deemed to be followed by the phrase “but not limited to,” “without
limitation” or words of similar import regardless of whether such words are actually written there (and drawing no implication
from the actual inclusion of such phrase in some instances after the word “including” but not others). References to
 “Article”, “Articles”, “Section”, Sections”, “Schedule” or “Schedule”
 “Exhibit” or “Exhibits” are references to the numbered Article(s), Section(s), Schedule(s) or lettered
Exhibit(s) of this Agreement, unless expressly stated otherwise. Except where the context otherwise requires, (a) references to
a particular law, rule or regulation mean such law, rule or regulation as in effect as of the relevant time, including all rules
and regulations thereunder and any successor law, rule or regulation in effect as of the relevant time, and including the then-current
amendments thereto; (b) the word “or” has the inclusive meaning that is typically associated with the phrase “and/or”;
(c) whenever this Agreement refers to a number of days, such number will refer to calendar days unless Business Days are specified,
and if a period of time is specified and dates from a given day or Business Day, or the day or Business Day of an act or event,
it is to be calculated exclusive of that day or Business Day; (d) references to a particular person or entity include such person’s
or entity’s successors and assigns to the extent not prohibited by this Agreement; (e) a capitalized term not defined herein
but reflecting a different part of speech than a capitalized term which is defined herein will be interpreted in a correlative
manner; and (f) the words “hereof,” “herein,” “hereby” and derivative or similar words refer
to this Agreement (including any Exhibits).

 

    -44-

     

    

 

12.13.   
  Headings. The captions or headings of the sections or other subdivisions hereof are inserted only as
a matter of convenience or for reference and shall have no effect on the meaning of the provisions hereof.

 

12.14.   
  No Implied Waivers; Rights Cumulative. No failure on the part of MedImmune or Aevi to exercise, and
no delay in exercising, any right, power, remedy or privilege under this Agreement, or provided by statute or at law or in equity
or otherwise, shall impair, prejudice or constitute a waiver of any such right, power, remedy or privilege or be construed as
a waiver of any breach of this Agreement or as an acquiescence therein, nor shall any single or partial exercise of any such right,
power, remedy or privilege preclude any other or further exercise thereof or the exercise of any other right, power, remedy or
privilege.

 

12.15.   
  Severability. If any provision hereof should be held invalid, illegal or unenforceable in any respect
in any jurisdiction, the Parties shall substitute, by mutual consent, valid provisions for such invalid, illegal or unenforceable
provisions, which valid provisions in their economic effect are sufficiently similar to the invalid, illegal or unenforceable
provisions that it can be reasonably assumed that the Parties would have entered into this Agreement with such valid provisions.
In case such valid provisions cannot be agreed upon, the invalidity, illegality or unenforceability of one or several provisions
of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid, illegal or unenforceable provisions
are of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered
into this Agreement without the invalid, illegal or unenforceable provisions.

 

12.16.   
  No Third Party Beneficiaries. No Person, other than Aevi, MedImmune and their respective Affiliates
and the Indemnitees under Article 11 and any permitted assignees hereunder, shall be deemed an intended beneficiary hereunder
or have any right to enforce any obligation of this Agreement.

 

12.17.   
  Dispute Resolution. With respect to any disputes between the Parties concerning this Agreement, the
dispute shall be submitted to escalating levels of Aevi and MedImmune senior management for review. If the dispute cannot be resolved
despite such escalation, then the matter may be referred by either Party to the Executive Officers to be resolved by negotiation
in good faith as soon as is practicable but in no event later than thirty (30) days after referral. Such resolution, if any, by
the Executive Officers shall be final and binding on the Parties. If the Executive Officers are unable to resolve such dispute
within such thirty (30) day period, each Party will be free to pursue all rights available to it under law or equity, provided
that it has complied with this Section 12.17. Notwithstanding the foregoing, either Party may seek emergency or temporary injunctive
relief in any court of competent jurisdiction.

 

12.18.   
  Execution in Counterparts. This Agreement may be executed in any number of counterparts and by facsimile
signature, each of which counterparts, when so executed and delivered, shall be deemed to be an original, and all of which counterparts,
taken together, shall constitute one and the same instrument.

 

    -45-

     

    

 

(signature page follows)

 

    -46-

     

    

 

IN WITNESS WHEREOF, the Parties have duly
executed this Agreement as of the Agreement Effective Date.

 

	AEVI GENOMIC MEDICINE, INC.	 	MEDIMMUNE LIMITED
	 	 	 
	By:	/s/ Michael F. Cola	 	By:	/s/ Adrian Kemp
	Name:	Michael F. Cola	 	Name:	Adrian Kemp
	Title:	President and Chief Executive Officer	 	Title:	Company Secretary

 

[Signature Page to Option and License
Agreement]

 

     

     

    

 

SCHEDULE
2.1.46

 

MEDIMMUNE
KNOW-HOW

 

The Parties agree to produce a definitive listing of the MedImmune
Know-How with (***) after the Agreement Effective Date. Such listing will contain, to the knowledge of MedImmune, substantially
all the Know-How Controlled by MedImmune as of the Agreement Effective Date with respect to the Molecule excluding MedImmune Excluded
IP including:

 

		1.	All study reports and databases in respect of in vitro (with respect to molecule efficacy) and animal testing of the
Molecule.

 

		2.	Copies of all correspondence to or from any Regulatory Authority concerning the Molecule and clinical testing thereof.

 

		3.	Copies of the INDs filed with the Regulatory Authorities in the United Kingdom and the Republic of South Africa with respect
to the Molecule and under which the clinical trial entitled “Phase I study to evaluate the safety and tolerability of
single ascending intravenous doses of MEDI2338 in subjects with stable, mild to moderate chronic obstructive pulmonary disease
(COPD)” was performed.

 

		4.	All study reports and databases in respect of the clinical trial referred to in Paragraph 3.

 

		5.	A listing of media and feeds (other than those included in the MedImmune Excluded IP) useful in propogating the Cell Lines.

 

		6.	The manufacturing batch records for the Cell Line, Antibody Material and Clinical Material, redacted to excluded MedImmune
Excluded IP.

 

		7.	Reference standards for the Molecule.

 

     

     

    

 

Schedule
2.1.47

 

MedImmune Patent
Rights

 

	Country	Filing Date	Filing Number	Grant Number	Grant Date	Status	Expiry
	(***)	(***)	(***)	 (***)	 (***)	(***)	 (***)
	(***)	(***)	(***)	 (***)	 (***)	(***)	 (***)
	(***)	(***)	(***)	 (***)	 (***)	(***)	(***)
	(***)	(***)	(***)	 (***)	 (***)	(***)	(***)
	(***)	(***)	(***)	(***)	(***)	(***)	(***)

 

     

     

    

 

SCHEDULE
4.2

 

ANTIBODY
MATERIAL TO BE PROVIDED TO AEVI

 

	Drug Name	Amount	Manufacture Date
	(***)	
         

        (***)
	(***)
	(***)	
         

        (***)
	(***)

 

     

     

    

 

SCHEDULE
4.3

 

CELL
LINE TO BE PROVIDED TO AEVI

 

	Description	Lot No.	Quantity	
        Storage

        Temperature
	
        Storage

        Location

	(***)	(***)	(***)	(***)	(***)
	(***)	(***)	(***)	(***)	(***)

 

     

     

    

 

EXHIBIT
A

 

Press Release

 

Aevi Genomic Medicine Enters into License
Agreement with AstraZeneca for Anti-IL-18 Antibody

 

Plan to enter Phase 2 in Adult Onset Still’s Disease
and other serious rare and orphan diseases

 

August 6, 2019 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX,
 “Aevi”) today announced that it has obtained the right to exercise an exclusive global license for MEDI2338, a Phase
2-ready fully human monoclonal antibody (mAb) that targets interleukin 18 (IL-18). The Company plans to initially develop MEDI2338
for adult onset Still’s disease (AOSD), a serious rare and orphan rheumatological disease with no currently approved biologic
therapies in the US. Further development for several other rare autoinflammatory disorders that are driven by IL-18 will follow.

 

Under the terms of the agreement, Aevi will have the right to
exercise an exclusive global license to develop and commercialize MEDI2338. The Company will pay a combined mid-single digit millions
in cash and equity upon exercise of the option, up to $162 million upon achievement of certain development and sales-related milestones
and tiered low double-digit royalties on global annual product sales. Exercising the option is contingent on Aevi securing additional
funding. The Company will be fully responsible for the development and commercialization of the program.

 

“We are very excited to license this program from AstraZeneca
and look forward to advancing this potential rare disease therapy into clinical development,” said Garry Neil, M.D., Chief
Scientific Officer at Aevi Genomic Medicine. “AOSD is a rare, life-altering inflammatory disease characterized by fevers,
rash and joint pain and striking elevation of IL-18. Many patients also suffer liver, cardiopulmonary and renal complications.
Patients have limited available therapeutic options. Because IL-18 appears to play a central role in the disease, we believe that
MEDI2338 could prove to be an effective treatment for these patients. A clear mechanism of action and safety profile have already
been established in patients.”

 

About Adult Onset Still’s Disease (AOSD)

 

Adult onset Still’s disease (AOSD) is a rare and severe
autoinflammatory disease affecting adults. The disease is similar to systemic onset juvenile idiopathic arthritis (sJIA), that
affects children. The etiology of AOSD is unknown with both genetic and infectious factors being implicated. The hallmarks of the
disease are persistent daily fever, rash and arthralgias. Many patients suffer complications including splenomegaly, heart and
liver disease. Some AOSD patients develop macrophage activation syndrome, a severe acute complication that may cause rapid multi-organ
failure and even death.

 

     

     

    

 

About MEDI2338 

 

MEDI2338 is a fully human anti-IL-18 monoclonal antibody which
binds IL-18. Aevi Genomic Medicine will exclusively license the composition of matter patents, and the Company expects to establish
new biological product exclusivity for 12 years from the date of FDA approval of the antibody in the U.S., and at least 10 years
from the date of first authorization in Europe.

 

About Aevi Genomic Medicine, Inc.

 

Aevi Genomic Medicine, Inc. is dedicated to unlocking the potential
of genomic medicine to translate genetic discoveries into novel therapies. Driven by a commitment to patients with pediatric onset
life-altering diseases, the Company’s research and development efforts include working with the Center for Applied Genomics
(CAG) at Children’s Hospital of Philadelphia (CHOP) to leverage novel genetic discoveries to progress our genomic medicine
strategy

 

Forward-looking Statements

 

This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact,
including (without limitation) those regarding the Company's financial position, its development and business strategy, its product
candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements
be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms
and phrases such as "estimate," "project," "intend," "forecast," "anticipate,"
 "plan," "planning, "expect," "believe," "will," "will likely," "should,"
 "could," "would," "may" or the negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks
or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially
from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking
statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate
any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations
with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of
these factors, the events described in the forward-looking statements contained in this release may not occur.

 

     

     

    

 

CONTACT: 

Aevi Genomic Medicine, Inc.

Mike Cola

Mike.cola@aevigenomics.com

 

Westwicke Partners

Chris Brinzey

+1-339-970-2843

Chris.brinzey@westwicke.com

 

 

MEDIA INQUIRIES:

FTI Consulting

Irma Gomez-Dib

+1-212-850-5761

+1-415-706-9155

http://irma.gomez-dib@fticonsulting.com

 

# # #

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}]]